Review article

Complex interplay between autophagy and oxidative stress in the development of pulmonary disease

Wojciech Ornatowski\textsuperscript{a}, Qing Lu\textsuperscript{a}, Manivannan Yegambaram\textsuperscript{a}, Alejandro E. Garcia\textsuperscript{a}, Evgeny A. Zemskov\textsuperscript{a}, Emin Maltepe\textsuperscript{b}, Jeffrey R. Fineman\textsuperscript{b,c}, Ting Wang\textsuperscript{d}, Stephen M. Black\textsuperscript{a,*}

\textsuperscript{a} Department of Medicine, The University of Arizona Health Sciences, Tucson, AZ, USA
\textsuperscript{b} Department of Pediatrics, The University of California, San Francisco, San Francisco, CA, USA
\textsuperscript{c} Cardiovascular Research Institute, University of California, San Francisco, San Francisco, CA, USA
\textsuperscript{d} Department of Internal Medicine, The University of Arizona Health Sciences, Phoenix, AZ, USA

ARTICLE INFO

Keywords:
Autophagy
Reactive oxygen species
Mitophagy
Oxidative stress
Mitochondria
Pulmonary disease

ABSTRACT

The autophagic pathway involves the encapsulation of substrates in double-membraned vesicles, which are subsequently delivered to the lysosome for enzymatic degradation and recycling of metabolic precursors. Autophagy is a major cellular defense against oxidative stress, or related conditions that cause accumulation of damaged proteins or organelles. Selective forms of autophagy can maintain organelle populations or remove aggregated proteins. Dysregulation of redox homeostasis under pathological conditions results in excessive generation of reactive oxygen species (ROS), leading to oxidative stress and the associated oxidative damage of cellular components. Accumulating evidence indicates that autophagy is necessary to maintain redox homeostasis. ROS activates autophagy, which facilitates cellular adaptation and diminishes oxidative damage by degrading and recycling intracellular damaged macromolecules and dysfunctional organelles. The cellular responses triggered by oxidative stress include the altered regulation of signaling pathways that culminate in the regulation of autophagy. Current research suggests a central role for autophagy as a mammalian oxidative stress response and its interrelationship to other stress defense systems. Altered autophagy phenotypes have been observed in lung diseases such as chronic obstructive lung disease, acute lung injury, cystic fibrosis, idiopathic pulmonary fibrosis, and pulmonary arterial hypertension, and asthma. Understanding the mechanisms by which ROS regulate autophagy will provide novel therapeutic targets for lung diseases. This review highlights our current understanding on the interplay between ROS and autophagy in the development of pulmonary disease.

1. Introduction

Autophagy ("self-eating" in Greek) is a cellular degradation and recycling process for cytosolic macromolecules and damaged organelles [1,2]. Autophagy is highly conserved in all eukaryotes, and it is required to maintain cellular homeostasis. Thus, almost all types of cells have basal levels of autophagy. Under normal conditions, autophagy regulates physiological functions in which cellular components have to be degraded, building blocks have to be formed, and the cell has to respond to stress [2]. Autophagy is also highly inducible by environmental insults and alterations in the autophagic cycle rate (flux) is commonly observed in response to stress [3]. In most cases, induction of autophagy in response to stress acts as a cytoprotective mechanism. However, excessive self-degradation can lead to cell death [4–6].

In mammalian cells, there are three primary types of autophagy: macroautophagy, microautophagy, and chaperone-mediated autophagy (CMA). All the three pathways deliver their cargo to the lysosome for degradation and recycling (Fig. 1) but are mechanistically different from one another [7,8]. Macroautophagy (hereafter referred to as autophagy) has been the most investigated and characterized mechanism of autophagy [9]. It is induced by several stimuli, such as nutrient deprivation and other cellular stressors [10]. In contrast to microautophagy and CMA, macroautophagy involves de novo synthesis of double-membrane vesicles, autophagosomes that are used to sequester cargo and subsequently transport it to the lysosome [7,11]. Microautophagy does not require autophagosomes but involves the direct engulfment of the cargo.

\textsuperscript{*} Corresponding author. Division of Translational and Regenerative Medicine, Department of Medicine, The University of Arizona Health Sciences, Tucson, AZ, 85724, USA.

E-mail address: steveblack@email.arizona.edu (S.M. Black).

https://doi.org/10.1016/j.redox.2020.101679

Received 22 June 2020; Received in revised form 20 July 2020; Accepted 4 August 2020

Available online 11 August 2020

2213-2317/© 2020 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
transport soluble cytosolic proteins to the vesicles of late endosomal units, and proteins involved in vesicular trafficking [18].

Chaperone-mediated autophagy: Substrate proteins containing a KFERQ-like motif are recognized by chaperone Hsc70 and co-chaperones and translocated into the lysosomal lumen in a process that requires the lysosomal receptor protein LAMP-2A. After all three types of autophagy, the resultant degradation products can be used for different purposes, such as new protein synthesis or energy production.

Fig. 1. Different types of autophagy. (A) Macroautophagy: A cytosolic substrate or “cargo” is enclosed by an isolation membrane (also called phagophore) to form a double-membrane vesicle, termed autophagosomes. The outer membrane of the autophagosome fuses with the lysosome, and the internal material is degraded in the autolysosome. Macroautophagy can also target selective cargo for degradation such as organelles, proteins, microbes, and RNA. (B) Microautophagy: Small cytosolic components are directly engulfed into the lysosome or late endosomes by membrane invagination. (C) Chaperone-mediated autophagy: Substrate proteins containing a KFERQ-like motifs are recognized by chaperone Hsc70 and co-chaperones and translocated into the lysosomal lumen in a process that requires the lysosomal receptor protein LAMP-2A. After all three types of autophagy, the resultant degradation products can be used for different purposes, such as new protein synthesis or energy production.

by the invagination of the lysosomal membrane [12,13]. Lysosomal enzymes directly access the cargo by degeneration of the inner membrane [5,6,13]. Recent studies have demonstrated that a microautophagy-like process called endosomal microautophagy can also transport soluble cytosolic proteins to the vesicles of late endosomal multivesicular bodies [14,15]. Unlike microautophagy and macroautophagy, which both nonspecifically engulf bulk cytoplasm, CMA is highly specific, and has so far only been described in mammalian cells. CMA differs from microautophagy in that it does not use membranous structures to sequester cargo, but instead involves the chaperone protein Hsc70 to identify proteins with a consensus KFERQ [16]. These proteins are recognized by the lysosome-associated membrane protein type 2a (LAMP2a) receptor, a major regulator of CMA, to transport them into the lysosomes for degradation [17]. CMA degrades a wide range of substrate proteins including certain glycolytic enzymes, transcription factors and their inhibitors, calcium and lipid binding proteins, proteasome subunits, and proteins involved in vesicular trafficking [18].

While nonspecific autophagy can be induced in response to nutrient or energy deprivation to enable cell survival, growing evidence suggests that autophagy has a more selective role in the delivery of a wide range of specific cytoplasmic cargo to the lysosome for degradation [19,20].

Selective autophagy processes are named after the specific targets, for example: “mitophagy” refers to the selective removal of mitochondria by autophagy [21,22]. Other forms of selective autophagy have been identified to engage in organelle turnover such as peroxisomes (pexophagy) [23], endoplasmic reticulum (ER)-phagy [24], portions of the nucleus (nucleophagy) [25], and ribosomes (ribophagy) [26]. Selective autophagy also has the capacity to clear lipids (lipophagy) [27], RNA (Rnautophagy) [28], microorganisms (xenophagy) [29], protein aggregates (aggrephagy) [30], cilia components (ciliphagy) [31], ferritin (ferritinnophagy) [32] and more recently, inflammasome complexes (inflammasomophagy) [33].

Interestingly, autophagy is regulated by reactive oxygen species (ROS) and oxidative stress [34,35]. Although the specific interactions between autophagy and oxidative stress have not been elucidated fully, it is known that autophagy can be modulated by oxidative stress, generally enhancing its induction [36–38]. Therefore, careful regulation of ROS and its interplay with autophagic degradation pathways is crucial for cellular homeostasis. It is also well established that both ROS and autophagy are strongly associated with pulmonary diseases, but clarifying the functional relationship of the two mechanisms has proven to be difficult due to their dual role in many disease processes. In this review, we will discuss the role of autophagy and its association with oxidative stress–mediated ROS signaling in the development and progression of pulmonary disease.

2. Molecular regulation of autophagy

The autophagy regulatory system consists of over 30 autophagy-related gene (ATG) products that are homologues of similar proteins (Atg) originally identified in yeast [39]. The whole process of autophagy involves a set of 15–20 core conserved ATG genes. ATGs are implicated in all the different steps of the autophagic process, which can be divided into initiation, nucleation, elongation, fusion, and degradation (Fig. 2).
Induction of autophagy can be triggered by several intracellular and extracellular stimuli, e.g. nutrient starvation including depletion of total amino acids [40], inhibitors of mTOR such as rapamycin [41], hypoxia [42], and oxidative stress [36]. Under autophagy-inducing conditions, the initiation of autophagy requires the formation of the Unc-51 like autophagy activating kinase 1 or 2 (ULK1/2) complex at the phagophore assembly site (PAS). In humans, this complex includes the ATG scaffolds ATG13, ATG101, and FIP200 [43] (Fig. 2). The activity of ULK1 kinase complex can be regulated by both mammalian target of rapamycin complex 1 (mTORC1) and AMP-activated protein kinase (AMPK). Growth factors and amino acids stimulate mTORC1 and negatively regulate autophagy by directly phosphorylating ULK1 and inhibiting its activity [44,45]. Upon mTOR inhibition by starvation or rapamycin, ULK1 and ULK2 are activated and ATG13 and FIP200 are phosphorylated, which is an essential step for autophagy activity [46–48] (Fig. 2).

Autophagy is also regulated by depletion of cellular energy through increased activity of AMPK. AMPK inactivates mTORC1 and phosphorylates and activates ULK1 to promote autophagy resulting in the degradation of cellular components to generate ATP [44,45,49]. The formation of ULK1/2 complex triggers the initiation of a double-membrane autophagosome formation. In mammals, however, the origin of the autophagosomal membrane is debated. Several studies suggest that endoplasmic reticulum (ER)-associated structures called omegasomes may contribute as initiation sites in mammals [50,51], other sources of membrane include ER-Golgi intermediate compartments [52], ER-mitochondria junctions [53], mitochondria [54], Golgi-endosomal membranes [55], and the plasma membrane [56].

Following the initiation step of autophagy, the nucleation stage involves the class III phosphatidylinositol 3-kinase (PI3K) complex consisting of Beclin 1, VPS34, VPS15, and ATG14 [57]. In mammalian cells, Beclin1 is a central component of PI3K complex. It interacts with a multitude of proteins including ATG14, UVRAG, Rubicon, and Bel-2 to regulate the size and number of autophagosomes [58–60]. Activation of the Beclin 1 is responsible for the generation of phosphatidylinositol 3-phosphate (PtdIns3P), which is required for the formation of the autophagosome [61]. PtdIns3P recruits accessory protein factors that include the double FYVE-containing protein-1 (DFCP1) and WD-repeat protein interacting with phosphoinositide (WIPI) proteins, to mediate the initial stages of autophagosome formation including the recruitment of ATG16L and subsequently, the ATG5-ATG12 conjugation system to the PAS [62]. In addition, ATG9-containing vesicles generated by the secretory pathway are recruited to the PAS allowing the delivery of additional lipids and proteins contributing to membrane expansion [63]. Recent studies suggest that AMPK-dependent ULK1 phosphorylation regulates the trafficking of ATG9 [57]. Non-canonical, Beclin 1-independent autophagy has also been reported [64,65].

After the activation of PtdIns3K complex, the phagophore expands and elongates by membrane addition, which is accomplished by two essential ubiquitin-like (Ubl) conjugation systems, which involve the Ubl proteins ATG12 and microtubule-associated protein light chain 3 (LC3) [66,67]. The covalent conjugation of ATG12 to ATGS involves ATG7 and ATG10 and is organized into a complex by a non-covalent association with ATG16L. This complex is essential for the elongation of the pre-autophagosomal membrane but dissociates from fully formed autophagosomes. The ATG12-ATG5-ATG16L complex localizes to the isolation membrane throughout its elongation process and serves as a ligase to promote LC3 conjugation with phosphatidylethanolamine (PE) [68]. The conjugation of PE to soluble LC3 (LC3-I) is mediated by the sequential action of the protease ATG4 (the sole protease in the ATG family), ATG7, and ATG3. Lipidation of LC3 facilitates its interaction with the forming autophagosomal membrane which facilitates cargo recruitment to autophagosomes, and allows expansion and closure of the isolation membrane to occur [69]. The lipidated form of LC3 (LC3-II) is specifically targeted to the elongating autophagosome and remains on autophagosomes until their fusion with lysosomes [70] (Fig. 2). LC3-II localized at the cytoplasmic face of autolysosomes is delipidated by ATG4 and recycled, while LC3-II found on the internal surface of autophagosomes is degraded in the autolysosomes [3]. Since LC3-II localizes to the autophagosome membranes, it is commonly used as an autophagy marker.

When initiation, nucleation, and elongation have completed, the expanding membrane closes around its cargo to form a complete autophagosome which fuses with lysosomes to form the autolysosome. The PtdIns3K complex, can activate the GTPase Rab7, which promotes fusion with lysosomes [71]. In addition, LAMP-2A, a lysosomal membrane protein, is required for the fusion of autophagosomes with lysosomes. Once fusion is complete, the autolysosome contents are degraded and the resulting molecules are released back into the cytosol as new energy sources for cell survival. In addition to providing new building blocks and energy sources, autophagy also helps to remove damaged organelles such as mitochondria as another important mechanism for cell survival [72].

3. The relationship between reactive oxygen species and autophagy

Dysregulation of ROS due to increased ROS generation and/or decreased local antioxidant defenses results in oxidative stress leading to oxidative damage of proteins, lipids, and nucleic acids [73,74]. Therefore, a balance between the generation and elimination of ROS is necessary for avoiding cell damage and this is critical for human health [75]. In biologic systems, ROS are generated by enzymatic and non-enzymatic redox reactions during cellular aerobic metabolism under both normal and pathological conditions, or upon exposure to environmental or xenobiotic agents. In general, ROS are comprised of oxygen free radicals such as superoxide (O$_2^-$) and hydroxyl radical (OH$^-$), as well as non-radical derivatives of oxygen, such as hydrogen peroxide (H$_2$O$_2$). These species are endogenously generated by several cell organelles including peroxisomes and mitochondria where approximately 90% of ROS (mtROS) are derived from the respiratory chain of the inner mitochondrial membrane [76,77]. Under physiological conditions, mitochondria produce very low levels of ROS. High ROS flux leads to irreversible alteration of target macromolecules contributing to the biological damage inside the cell associated with a number of physiological conditions, such as aging and senescence, as well as pathological states, such as cancer and neurodegeneration. Conversely, basal or physiological levels of ROS play an important homeostatic role in regulating cell proliferation, growth factor signaling, immune responses, differentiation, and autophagy [78,79]. To maintain cellular redox homeostasis, mammalian cells produce antioxidant enzymes and non-enzyme agents including superoxide dismutase (SOD), catalase, peroxidases, glutathione, and thioredoxin, which antagonize and detoxify ROS [80,81]. ROS-mediated oxidation of macromolecules and organelles or mild oxidative stress activate the autophagy pathway to eliminate damaged macromolecules and protein aggregates to maintain cellular homeostasis. Autophagy is one of the most important biological responses regulated by ROS and oxidative stress. Alterations in cellular redox state could be both, a trigger for and a regulator of autophagy, in contrast autophagy could be used by cells as a mechanism for regulating redox metabolism under various stress conditions [82,83]. Autophagy also regulate levels of ROS by other pathways such as the CMA-, p62 delivery-, mitophagy-, and pexophagy-pathways.

There is a growing consensus that the oxidative stress associated with increases in reactive oxygen species (ROS) and autophagy are intricately connected (Fig. 3). Autophagy can be regarded as a secondary defense to oxidative stress, by virtue of its ability to facilitate the turnover of damaged substrates which may accumulate during this process. ROS participate in the interplay between autophagy and apoptosis by ROS ability to mediate the redox signaling pathways [37,84]. This interaction triggers an autophagy response, which further induces oxidative stress when the autophagy function is disrupted. Under starvation conditions, ROS originating from mitochondria and NADPH oxidases...
activate autophagy to provide protection from nutrient starvation via the autophagic elimination of damaged organelles [85]. Moreover, autophagy is also a mechanism for the removal of damaged and dysfunctional mitochondria (mitophagy) that themselves are a significant source of oxidative stress. The removal of damaged mitochondria by mitophagy plays important role in cellular antioxidant defenses, by preventing pathological mitROS generation [86]. The regulation of the mammalian antioxidant response also overlaps with that of autophagy. Autophagy is crucial in ROS generation and scavenging, which is achieved by the release and activation of nuclear factor erythroid 2-related factor 2, Nrf2 [87]. Ubiquitin-binding protein p62 enhances Keap-1-Nrf2 dissociation and facilitates degradation of Keap1 by p62-dependent autophagy, further stimulating the antioxidant response [88,89]. In addition, sestrins (SESNs), proteins involved in protecting cells from oxidative stress also promote p62-dependent autophagic degradation of Keap-1 [90]. Therefore, there is a close relationship between oxidative stress and autophagy where oxidative stress can induce autophagy through various mechanisms and vice-versa [36,91]. The following sections describe in more detail the complex interplay between ROS and autophagy.

3.1. Role of free radicals in autophagy regulation

There are several major sources of free radicals in cells including NADPH oxidase (NOX), xanthine oxidase, the mitochondrial electron transport chain (ETC), and nitric oxide synthase (NOS). Further, there are a number of free radicals produced within the cell including superoxide (O$_2^-$) the hydroxyl radical (OH), nitric oxide (NO), and peroxynitrite from the interaction of NO with O$_2^-$ and H$_2$O$_2$. There is a significant amount of literature that demonstrates the crosstalk between free radical generating systems and autophagy (Fig. 3 and Table 1). The NOX family consists of at least 7 members: NOX1-5 and DUOX-1 and -2 [92]. There is a significant amount of evidence that NOX isoforms are involved in the regulation of autophagy. However, the role of NOX in autophagy regulation appears to be dependent on the disease pathology. For example, increases in NOX1 (and NOX4) have been shown to be involved in increase in autophagy associated with HI injury [93], in transport stress in the pig jejunum [94], and in the decrease in angiogenesis associated with persistent pulmonary hypertension of the newborn (PPHN) [95]. Further, in the latter study a positive feedback relationship between autophagy and NOX activity was identified [95]. Conversely, and increase in NOX1 (and NOX4) expression in Retinal neovascularization (RNV) NOX1 (and NOX4) is associated with decreased autophagy flux [96]. Similarly, in high fat-fed mice, increased NOX2 activity appears to result in impaired lysosomal acidification and reduced autophagic flux [97]. However, the increase in autophagy associated with Parkinson’s disease is associated with increases in multiple NOX isoforms: NOX1, NOX2, and NOX4 and these increases occur in both microglia and neurons within the substantia nigra of the brain [98]. Multiple NOX isoforms (NOX2, NOX4, and NOX5 but not NOX1) are also associated with the activation of autophagy associated with starvation stress in retinal pigment epithelial cells (RPE) [99]. In cultured rat cardiomyocytes, removing extracellular glucose triggers an increase in ROS that was dependent on NOX4 activity within the endoplasmic reticulum [100]. This NOX4-dependent increase in ROS induced a corresponding increase in autophagic flux [100]. In addition, NOX4-derived ROS appeared to trigger a transcriptional program mediated through a pathway involving protein kinase RNA-activated-like ER kinase (PERK) [101]. Although there is no evidence for NOX3 in regulating autophagy, DUOX has been shown to be activated downstream of autophagy in Drosophila [102,103]. Like NOX, XO appears to be able to be regulated by autophagy [104,105] and to regulate autophagy [186] although there is significantly less literature on this area which is a significant limitation in the field that needs to be addressed. Starvation-induced autophagy has been shown to depend on mitochondrial O$_2^-$ formation, which also regulates adenosine monophosphate-dependent protein kinase (AMPK) activation [107]. Moreover, amino acid deprivation induces the formation of H$_2$O$_2$ in mitochondria in a PI3KCIII-dependent manner, and this has also been linked to the induction of autophagy in response to starvation [108]. In addition, H$_2$O$_2$ can diffuse into the lysosome, particularly in neuronal

| Table 1 | Autophagy-Free radical cross-talk. |
|---------|----------------------------------|
| Source of free radical | Regulator of autophagy | Regulated by Autophagy |
| NOX1    | ✓                               | ✓                           |
| NOX2    | ✓                               | ✓                           |
| NOX3    | ?                               | ?                           |
| NOX4    | ✓                               | ✓                           |
| NOX5    | ✓                               | ✓                           |
| DUOX1   | ✓                               | ✓                           |
| DUOX2   | ?                               | ?                           |
| Xanthine oxidase (XO) | ✓ | ✓ |
| mitochondrion | ✓ | ✓ |
| NOS     | ✓                               | ?                           |
cells, possibly undergoing Fenton like reactions to generate highly reactive OH [109]. OH is capable of reacting with the multitude of hydroxides in the lysosome, decreasing their ability to degrade molecules delivered to the lysosome. Hypoxia, or reduced pO2, also results in impaired mitochondrial electron transport chain activity, increased mitochondrial O2 production, and mitochondrial dysfunction [110].

Under oxidative conditions Atg4 is oxidized and inactive, which allows lipidation of LC3 and the subsequent initiation of autophagy, revealing that the modulation of the action of Atg4 on LC3 can be controlled by H2O2 [34]. Other evidence suggests that H2O2 induces autophagy through a Beclin-1 dependent pathway that is associated with autophagic cell death [35].

There is also a significant literature demonstrating the involvement of NO in the regulation of autophagy. This appears to be linked to the role of NO in regulating apoptosis. However, conflicting roles of NO in regulating apoptosis and autophagy have been reported. For example, the induction of autophagy by NO is intimately involved in the survival of human dental pulp cells (HDPCs) against NO-induced apoptosis [111] and induces autophagy but not apoptosis in K562 cells [112]. Conversely, in acute liver failure, NO promotes apoptosis through autophagy inhibition in hepatic stellate cells [113]. A similar NO-mediated inhibition of autophagy is observed in hepatocellular carcinoma [114]. Interestingly in plants, there appears to be a yin-yang relationship between NO and ROS in regulating autophagy with NO suppressing, and ROS activating, autophagy [115]. As a number of vascular diseases are associated with a loss of NO signaling this could be another mechanism by which autophagy is stimulated during the disease process. One of the major sources of peroxynitrite is uncoupled NOS in which there is an uncoupling between the oxidation of NADH and the generation of NO [116]. Prevailing, though limited, data indicate that peroxynitrite is a regulator of autophagy. For example, Wogonin stimulates apoptosis in gastric cancer cells through increases in peroxynitrite generation [117] and peroxynitrite is involved in the excessive mitophagy associated with ischemia-reperfusion injury [118]. Peroxynitrite interacts with exposed tyrosine residues in certain proteins to form a covalent modification called a nitrotyrosine residue. However, at present only the transient receptor potential melastatin-related 2 (TRPM2) channel has been identified as a peroxynitrite target that stimulates autophagy [119]. It is critical to determine if there are other protein targets within the autophagy pathway susceptible to protein nitration and determine how the introduction of nitrotyrosine residues alters autophagy activity in different disease states.

3.2. The regulation of autophagy by ROS

Autophagy is activated in response to oxidative stress to protect the cells from apoptosis [120], whereas autophagy inhibition causes accumulation of oxidative stress damage and cell death [121]. Increased production of ROS activates the HIF-1α transcription factor, p53, FOXO3, and Nrf2. These transcription factors then induce the transcription of BNIP3 and NIX, TIGAR, LC3 and p62 [121]. Studies using nutrient deprivation have identified increases in O2•− [85] or H2O2 [108] as early inducers of autophagy [36]. In mammalian cells, H2O2 induces autophagy, via increased Beclin 1 expression and mTOR inhibition, and inhibiting autophagy stimulates apoptosis [122]. Increased generation of mitochondrial H2O2 oxidizes and inactivates a critical cysteine residue (Cys48) on ATG4 catalytic site [123]. Oxidized ATG4 is then capable of promoting lipidation of LC3 for autophagy initiation, followed by autophagosome formation. It was recently demonstrated that the vasoconstrictor effect of angiotensin II (Ang II) is associated with the induction of autophagy, suggesting that Ang II can stimulate the elongation of the phagophore via the development of LC3-containing autophagic vesicles and increases in ATG12–ATG5, ATG7 and ATG4 [124]. In human glomerular mesangial cells, Ang II-induced oxidative stress promotes autophagy via mTORC1 signaling causing early senescence [125]. In addition, Li et al. [126] found that the growth inhibitory effect of N-Benzoyl-O-d-phenylalanyl-d-phenylalaninol (BBP) involves induction of the autophagy in MCF-7 cells, which is modulated by ATG4 upregulation that requires increased ROS production.

Studies have shown that ROS regulate autophagy via mTOR-dependent pathways in the cytoplasm [37,127]. ROS can activate autophagy by inhibiting the PI3K-Akt-mTOR pathway or by activating AMPK to inhibit the mTOR signaling pathway [128]. Akt-mTOR activity is inhibited by elevated levels of ROS which oxidize phosphatase and tensin homologue (PTEN) [129]. Similarly, excess H2O2 can induce autophagy in an AMPK-dependent manner and this is accompanied by decreased mTORC1 activity [18]. Thioredoxin-interacting protein (TXNIP), has also been shown to regulate autophagy in a rat model of diabetic nephropathy again through the mTOR signaling pathway [130]. In addition, MAPK-p38 are responsive to the kinase apoptosis-signal kinase-1 (ASK-1), which is maintained in an inactive state until it is release by ROS-mediated oxidation of TXNIP [131]. It is also well established that SESNs are involved in regulating mTOR signaling by activating AMPK [82,132]. After exposure to cellular stress, increased levels of SESN2 can activate AMPK, resulting in the negative regulation of mTOR [132]. Morsch and colleagues [133] observed reduced SESN2 protein levels and AMPK phosphorylation, and increased mTOR phosphorylation in mice exposed to cigarette smoking for 45 days. Furthermore, mTORC2 activity is also sensitive to the redox state [134]. ROS and starvation combine increase mTORC2 signaling, leading to long-term cell cycle arrest, senescence, or differentiation [135] (Fig. 3).

Hypoxia, which is often seen in lung diseases, due to reduced lung function in these diseases is a major stimulus for the induction of autophagy [136]. Hypoxia can result in impaired mitochondrial electron transport chain activity, increased mitochondrial O2 production, and mitochondrial dysfunction [136–139]. Depending upon the degree of severity and duration of oxygen deprivation, hypoxia triggers different pathways of autophagy. Moderate and chronic hypoxia trigger HIF-1α as well as PKG–JNK1-mediated pathways to induce autophagy [42]. In moderate hypoxia, ROS can activate Beclin 1 dependent autophagy, as BNIP3, a protein that is upregulated by HIF-1α, prevents Bcl-2-mediated inhibition of Beclin 1 and free Beclin 1 induces autophagy [136]. Deletion of BECN1 or BNIP3 promotes hypoxia-induced cell death. It has been shown that stabilization of HIF-1α under hypoxia is dependent on the PI3K-Akt pathway [140]. Moreover, ROS accumulation mediated by hypoxia exposure triggers the activation of p38 and JNK-MAPK and stimulates BNIP3-induced autophagy [141]. Conversely, severe oxygen fluctuations induce autophagy via a HIF-1α-independent pathway [142] and unfolded protein response (UPR) [143]. In primary human lung vascular endothelial and smooth muscle-cells, hypoxia induces the expression of BECN1, causes LC3 activation, increases autophagosome formation, and stimulates autophagic flux resulting in protection against pulmonary vascular disease in mice [144].

Several studies have shown that ROS regulate Rhoa GTase activity, and Rhoa, in turn, controls cellular redox balance by modulating the enzymes involved in ROS generation [145–147]. Autophagy has been shown to target and degrade active Rhoa [148]. Intriguingly, Rhoa can repress signaling through mTORC1, thus enhancing autophagy in a potential negative feedback loop [149]. When exposure to ROS becomes chronic, a long-term response is generated via the activation of specific transcriptional networks including the transcription factor and tumor suppressor, p53 [150]. p53-induced glycolysis and apoptosis regulator (TIGAR) is a p53 target interacts with hexokinase II (HKII), which modulates the glycolysis pathway, upregulating NADPH production and reducing mROS levels [151,152]. Inhibition of TIGAR induces mROS production and autophagy, whereas overexpression of TIGAR alleviates autophagy [108]. Moreover, p53-induced SESN1 and SESN2 increases autophagy via the activation of AMPK and the subsequent inhibition of mTORC1 [153]. In contrast, the sulfhydryl group-containing ubiquitin-like enzymes Atg3, Atg7, and Atg10 are redox-sensitive in a manner similar to the E1 and E2 enzymes of the ubiquitin system, and
3.3. Autophagy regulates ROS formation

Autophagy is a potential survival mechanism during oxidative stress by removing damaged cellular components [36,91]. Importantly, the removal of damaged mitochondria by mitophagy plays a crucial role in cellular antioxidant defense, by maintaining mitochondrial quality control and preventing pathological mTOR generation [86]. This represents a mechanism of negative feedback regulation by which autophagy eliminates the source of oxidative stress and protects the cell from oxidative injury. The beneficial role of autophagy in oxidative stress has been highlighted in genetic models of defective autophagy, which manifest with increased sensitivity to oxidative stress. In cells with conditional autophagy has also been observed in mouse models of Duchenne’s muscular dystrophy [159]. Finally, it has been reported that CFP deficiency causes defective autophagic flux in both human airway epithelial cells and nasal biopsies from CF patients, leading to the formation of aggresomes through the production of ROS, upregulation of tissue transglutaminase (TG2), and subsequent accumulation of p62 [160]. Since autophagy is one of the primary mechanisms by which cells moderate ROS, autophagy impairment can generate a vicious feed-forward loop, where inability to remove elevated ROS levels leads to further ROS production, which may trigger cell death, and lead to disease progression.

3.3. Autophagy regulates ROS formation

Autophagy is a potential survival mechanism during oxidative stress by removing damaged cellular components [36,91]. Importantly, the removal of damaged mitochondria by mitophagy plays a crucial role in cellular antioxidant defense, by maintaining mitochondrial quality control and preventing pathological mTOR generation [86]. This represents a mechanism of negative feedback regulation by which autophagy eliminates the source of oxidative stress and protects the cell from oxidative injury. The beneficial role of autophagy in oxidative stress has been highlighted in genetic models of defective autophagy, which manifest with increased sensitivity to oxidative stress. In cells with conditional autophagy has also been observed in mouse models of Duchenne’s muscular dystrophy [159]. Finally, it has been reported that CFP deficiency causes defective autophagic flux in both human airway epithelial cells and nasal biopsies from CF patients, leading to the formation of aggresomes through the production of ROS, upregulation of tissue transglutaminase (TG2), and subsequent accumulation of p62 [160]. Since autophagy is one of the primary mechanisms by which cells moderate ROS, autophagy impairment can generate a vicious feed-forward loop, where inability to remove elevated ROS levels leads to further ROS production, which may trigger cell death, and lead to disease progression.

3.3. Autophagy regulates ROS formation

Autophagy is a potential survival mechanism during oxidative stress by removing damaged cellular components [36,91]. Importantly, the removal of damaged mitochondria by mitophagy plays a crucial role in cellular antioxidant defense, by maintaining mitochondrial quality control and preventing pathological mTOR generation [86]. This represents a mechanism of negative feedback regulation by which autophagy eliminates the source of oxidative stress and protects the cell from oxidative injury. The beneficial role of autophagy in oxidative stress has been highlighted in genetic models of defective autophagy, which manifest with increased sensitivity to oxidative stress. In cells with conditional autophagy has also been observed in mouse models of Duchenne’s muscular dystrophy [159]. Finally, it has been reported that CFP deficiency causes defective autophagic flux in both human airway epithelial cells and nasal biopsies from CF patients, leading to the formation of aggresomes through the production of ROS, upregulation of tissue transglutaminase (TG2), and subsequent accumulation of p62 [160]. Since autophagy is one of the primary mechanisms by which cells moderate ROS, autophagy impairment can generate a vicious feed-forward loop, where inability to remove elevated ROS levels leads to further ROS production, which may trigger cell death, and lead to disease progression.

3.3. Autophagy regulates ROS formation

Autophagy is a potential survival mechanism during oxidative stress by removing damaged cellular components [36,91]. Importantly, the removal of damaged mitochondria by mitophagy plays a crucial role in cellular antioxidant defense, by maintaining mitochondrial quality control and preventing pathological mTOR generation [86]. This represents a mechanism of negative feedback regulation by which autophagy eliminates the source of oxidative stress and protects the cell from oxidative injury. The beneficial role of autophagy in oxidative stress has been highlighted in genetic models of defective autophagy, which manifest with increased sensitivity to oxidative stress. In cells with conditional autophagy has also been observed in mouse models of Duchenne’s muscular dystrophy [159]. Finally, it has been reported that CFP deficiency causes defective autophagic flux in both human airway epithelial cells and nasal biopsies from CF patients, leading to the formation of aggresomes through the production of ROS, upregulation of tissue transglutaminase (TG2), and subsequent accumulation of p62 [160]. Since autophagy is one of the primary mechanisms by which cells moderate ROS, autophagy impairment can generate a vicious feed-forward loop, where inability to remove elevated ROS levels leads to further ROS production, which may trigger cell death, and lead to disease progression.

3.3. Autophagy regulates ROS formation

Autophagy is a potential survival mechanism during oxidative stress by removing damaged cellular components [36,91]. Importantly, the removal of damaged mitochondria by mitophagy plays a crucial role in cellular antioxidant defense, by maintaining mitochondrial quality control and preventing pathological mTOR generation [86]. This represents a mechanism of negative feedback regulation by which autophagy eliminates the source of oxidative stress and protects the cell from oxidative injury. The beneficial role of autophagy in oxidative stress has been highlighted in genetic models of defective autophagy, which manifest with increased sensitivity to oxidative stress. In cells with conditional autophagy has also been observed in mouse models of Duchenne’s muscular dystrophy [159]. Finally, it has been reported that CFP deficiency causes defective autophagic flux in both human airway epithelial cells and nasal biopsies from CF patients, leading to the formation of aggresomes through the production of ROS, upregulation of tissue transglutaminase (TG2), and subsequent accumulation of p62 [160]. Since autophagy is one of the primary mechanisms by which cells moderate ROS, autophagy impairment can generate a vicious feed-forward loop, where inability to remove elevated ROS levels leads to further ROS production, which may trigger cell death, and lead to disease progression.

3.3. Autophagy regulates ROS formation

Autophagy is a potential survival mechanism during oxidative stress by removing damaged cellular components [36,91]. Importantly, the removal of damaged mitochondria by mitophagy plays a crucial role in cellular antioxidant defense, by maintaining mitochondrial quality control and preventing pathological mTOR generation [86]. This represents a mechanism of negative feedback regulation by which autophagy eliminates the source of oxidative stress and protects the cell from oxidative injury. The beneficial role of autophagy in oxidative stress has been highlighted in genetic models of defective autophagy, which manifest with increased sensitivity to oxidative stress. In cells with conditional autophagy has also been observed in mouse models of Duchenne’s muscular dystrophy [159]. Finally, it has been reported that CFP deficiency causes defective autophagic flux in both human airway epithelial cells and nasal biopsies from CF patients, leading to the formation of aggresomes through the production of ROS, upregulation of tissue transglutaminase (TG2), and subsequent accumulation of p62 [160]. Since autophagy is one of the primary mechanisms by which cells moderate ROS, autophagy impairment can generate a vicious feed-forward loop, where inability to remove elevated ROS levels leads to further ROS production, which may trigger cell death, and lead to disease progression.

3.3. Autophagy regulates ROS formation

Autophagy is a potential survival mechanism during oxidative stress by removing damaged cellular components [36,91]. Importantly, the removal of damaged mitochondria by mitophagy plays a crucial role in cellular antioxidant defense, by maintaining mitochondrial quality control and preventing pathological mTOR generation [86]. This represents a mechanism of negative feedback regulation by which autophagy eliminates the source of oxidative stress and protects the cell from oxidative injury. The beneficial role of autophagy in oxidative stress has been highlighted in genetic models of defective autophagy, which manifest with increased sensitivity to oxidative stress. In cells with conditional autophagy has also been observed in mouse models of Duchenne’s muscular dystrophy [159]. Finally, it has been reported that CFP deficiency causes defective autophagic flux in both human airway epithelial cells and nasal biopsies from CF patients, leading to the formation of aggresomes through the production of ROS, upregulation of tissue transglutaminase (TG2), and subsequent accumulation of p62 [160]. Since autophagy is one of the primary mechanisms by which cells moderate ROS, autophagy impairment can generate a vicious feed-forward loop, where inability to remove elevated ROS levels leads to further ROS production, which may trigger cell death, and lead to disease progression.
in the degradation of oxidized protein aggregates via their incomplete degradation within the lysosomal compartment. Finally, CMA has also been demonstrated to be involved in the turnover of oxidized proteins [190]. As previously described, CMA is the type of autophagy wherein a particular pool of substrate proteins is recognized by a chaperone–co-chaperone complex, with this complex delivering them to lysosome for degradation. Several components of the lysosomal translocation complex, such as the chaperoning activities of Hsp70 and Hsc70, as well as transcriptional up-regulation of LAMP-2A, are induced under oxidative stress [190,191]. Protein oxidation causes partial unfolding, not only exposing hidden recognition motifs for Hsc70 binding but also facilitating translocation to the lysosomal lumen. The process of protein unfolding can also expose hidden CMA-targeting motifs, which may facilitate their recognition by the cytosolic chaperone complex [190]. Another possibility is that oxidation of certain residues creates a previously non-existing KFERQ-like motif [121]. Exposure of CMA-incompetent cells to oxidant factors results in more severely compromised cell viability than in cells with preserved CMA function [192]. The impairment of CMA also up-regulates macroautophagy in order to maintain normal rates of long-lived protein degradation. Interestingly, up-regulation of macroautophagy is unable to compensate for the increased sensitivity of CMA-deficient mouse fibroblasts to oxidative stress [192]. Furthermore, inhibition of CMA stimulates accumulation of GAPDH, AKT1 phosphorylation, generation of ROS, and cellular apoptosis [193]. Significantly, a deletion of LAMP2, a major regulator of CMA, impairs mitochondrial health and increases ROS-induced cell death [194].

3.4. Autophagy and the antioxidant response

Numerous studies suggest a cross talk between antioxidant enzyme upregulation following oxidative stress and enhanced autophagy [36, 195,196]. The oxidative stress response transcription factor CCAAT/enhancer-binding protein (C/EBP) mediates interaction with the antioxidant-response element (ARE) [199] or electrophile response element (EpRE) [200]. Under normal growth conditions, C/EBPs levels in the cell are kept low due to proteasomal degradation by the Kelch-like ECH-associated protein 1 (Keap1) that functions as an adapter protein of the Cul3-ubiquitin E3 ligase complex, which ubiquititates C/EBPs [197]. In response to oxidative stress, C/EBPs disassociate from its cytoplasmic inhibitor Keap1 and the released C/EBPs translocates to the nucleus where it binds to AREs in the promoter regions of antioxidant genes [197,198,201]. A number of oxidative agents modify cysteine residues on Keap1, resulting in conformational changes that prevent the degradation of newly synthesized C/EBPs. This results in a rapid accumulation of C/EBPs in the cell. In addition to regulation of antioxidant genes, C/EBPs can regulate the transcription of p62, a protein involved in cargo recognition and autophagy. In this process, p62 interacts with the Nrf2-binding site on Keap1, and mTORC1-dependent phosphorylation of p62 significantly increases the binding affinity of p62 for Keap1, allowing release of Nrf2 and subsequent transcriptional activation of Nrf2 target genes [202]. Several studies have demonstrated that the Keap1-p62 complex formed in this process is recruited to the autophagosome by LC3, and subsequently degraded by autophagy [201–203] (Fig. 3). Nrf2 induces p62 gene expression in response to oxidative stress, leading to a further increase in Nrf2 [87,201]. Therefore, p62 participates in a positive-feedback loop to maintain the Nrf2 anti-oxidant effect through increased autophagy [201]. Nrf2−/− mice display increased oxidative stress, impaired antioxidant responses and decreased cardiac autophagy after high intensity exercise [204]. Thus, the disruption of the Nrf2-Keap1 pathway can suppress autophagy while autophagy deficiency leads to the overexpression of the Nrf2-Keap1 pathway. The regulation and co-ordination of Keap1–Nrf2 and the autophagy pathway are essential for cell growth, differentiation, redox signaling and survival, has been addressed in several studies [205,206]. A recent investigation showed that during prolonged exposure of oxidative stress, using tert-butyl hydroperoxide (TBHP), Nrf2 negatively regulates autophagy through the down-regulation of AMPK [207]. A recent report described a novel pathway for mitophagy where p62 translocates Keap1 to the mitochondria to ubiquitinate this organelle and trigger mitophagy [208]. Nrf2 can also regulate PINK1 expression during oxidative stress [209], highlighting the complex links between Nrf2 and mitophagy. Accordingly, Keap1 inhibitors trigger mitophagy [210]. Therefore, the p62-positive-feedback loop likely protects against oxidative stress-dependent cell death by increasing mitophagy. As Nrf2 can also regulate mitochondrial biogenesis [211], it can be considered a central regulator of mitochondrial homeostasis.

The expression of sestrins or SESNs is induced by oxidative stress as a cellular antioxidant response. SESNs promote an antioxidant adaptive response in cells by activating transcription factors, such as p53, Nrf2, AP-1, and FoxO3s. Increasing evidence indicates that SESNs are positive regulators of autophagy in the face of diverse environmental stresses [212–214]. Although, there are some distinct differences in the functional biology of the various SESNs, they all converge to trigger activation of anti-oxidant factors and promote autophagy. SESNs have been shown to prevent ROS accumulation via inhibition of mTORC1 or stimulation of the Nrf2 [215]. Moreover, given that activation of mTORC1 increases the abundance of SESNs, SESNs are also negative feedback regulators of mTORC1 signaling. Studies indicate that SESN-dependent AMPK induction is important for mTORC1 suppression in diverse cellular contexts [216,217] (Fig. 3). SESN1 is induced by H2O2 in a p53-dependent manner, whereas the induction of SESN2 by oxidative stress is only partially dependent on p53 activation [218]. Overexpression of SESN1 or SESN2 induces autophagic degradation of Keap1 and increased Nrf2 activity [212]. Common themes in the experiments have revealed that SESN2 interacts directly with p62 and promotes the autophagic degradation of p62-dependent targets, including Keap1, thus upregulating the transcription of antioxidant genes [219] and the depletion of SESN2 results in the accumulation of ROS [220]. SESN2 is also a substrate of ULK1 and its phosphorylation mediates mTORC1 inhibition [221], highlighting the complex crosstalk between the sestrin family and autophagy in regulating cellular redox metabolism. Beyond that, mitochondrial HKII shares an extensive relationship with autophagy and redox homeostasis. HKII induces the inactivation of mTORC1 and creates a preventive antioxidant defense by decreasing release of ROS [222].

Taken together, intracellular oxidative stress significantly regulates autophagy. Meanwhile, autophagy also regulates ROS levels in cells via the mitophagy-, pexophagy-, proteasomal-, and CMA-pathways. In addition, autophagy can directly regulate antioxidant pathways (i.e., Nrf2 and SESNs pathways) to modulate redox homeostasis and cell survival.

4. Autophagy and ROS in pulmonary diseases

Autophagy plays a crucial role in lung homeostasis through several mechanisms, including the preservation of mitochondrial homeostasis and the removal of misfolded proteins [3,6]. As diverse pathophysiological roles of autophagy have been revealed, a number of studies exploring the roles of autophagy in pulmonary disease also have been reported [1]. Redox homeostasis has been shown to be altered in a variety of pulmonary diseases in both in vitro and experimental animal models [224]. In this section, we will discuss the role of ROS and imbalances in lung redox homeostasis signaling pathways in which autophagy is implicated in experimental pulmonary disease models and patients with pulmonary pathogenesis of chronic obstructive pulmonary disease, acute lung injury and sepsis, cystic fibrosis, idiopathic pulmonary fibrosis, pulmonary arterial hypertension, and asthma (Fig. 4).
4.1. Chronic obstructive pulmonary disease (COPD)

Chronic obstructive pulmonary disease (COPD) is a respiratory condition caused by direct and long-time exposure to toxic particles or gases that triggers airway or alveolar abnormalities, and typically presents with persistent respiratory symptoms and airflow limitations [225]. COPD includes both chronic bronchitis and emphysema. One of the major risk factors for COPD is cigarette smoke (CS). Epithelial cells lining the airways and alveoli are the primary targets of inhaled CS. Immune system dysregulation in response to the inhalation of CS drives prolonged and exaggerated inflammation in the lung, which contributes to the development of COPD. Other environmental factors include passive smoking, air pollution, and workplace exposure to dust, smoke or fumes [226,227]. COPD pathogenesis has been linked to excessive increases in autophagy and mitophagy (Fig. 4) which leads to epithelial programmed cell death leading to pulmonary emphysema [228–230]. Polymorphisms in the autophagy gene ATG16L have been shown to be a significant genetic risk factor for susceptibility to COPD, and autophagy is also increased in lung epithelium in patients with a genetic variant of emphysema, α1-antitrypsin deficiency (α1-AT) [231]. CS has been shown to produce abnormal autophagy and mitophagy leading to bronchial programmed cell death via apoptosis [224,230]. Further, impaired airway clearance caused by ciliosuppression-regulated cilia shortening may prevent the elimination of pathogens from the airways, resulting in recurrent respiratory infections that exacerbate COPD.

In vitro studies using cultured epithelial cells subjected to aqueous cigarette smoke extract (CSE) have revealed increases in autophagosome formation and accumulation of LC3-II. Conversely, the inhibition of autophagy by silencing LC3B protects epithelial cells from CSE-induced apoptosis [228]. Additionally, expression of the active form of LC3, LC3-II, as well as ATG4b, ATG5, ATG12, and ATG7 levels are significantly increased in COPD lungs [232]. Alterations in mTOR signaling has also been linked to CS-induced COPD/emphysema. Pre-clinical studies using both human lung cells and tissues have shown that autophagy mediates accumulation of aggresome-bodies primarily comprised of aggregated (misfolded or damaged) proteins triggers chronic inflammatory-apoptotic responses leading to senescence and emphysema progression [233–235]. Acute CS exposure only initiates moderate changes in autophagy, but with chronic exposures autophagy-flux is impaired [233,236]. CS-induced mitochondrial-dysfunction and lack of mitophagy also combine to induce cellular senescence and the progression of COPD. Recent studies have shown that oxidative stress can accelerate aging by depleting stem cells, accumulation of dysfunctional mitochondria, and decline in autophagy, all of which generate additional oxidative stress [237].

Current treatment measures for COPD include administration of bronchodilators, inhaled or oral steroid medications, antibiotics, anti-inflammatory drugs and anti-oxidants but these therapies do little to prevent the progression of the disease [238]. Therefore, enhancing mitophagy in human lung cells could prevent the accumulation of damaged mitochondria and the associated cellular senescence, and presents a potential therapeutic strategy in COPD [239].

4.2. Acute lung injury (ALI) and ventilator-induced lung injury (VILI)

Acute lung injury (ALI) and its more severe form acute respiratory distress syndrome (ARDS) is a life-threatening syndrome characterized by uncontrolled inflammation, oxidative injury, alveolar edema, and alveolar-capillary barrier disruption, leading to respiratory failure [240]. Autophagy is induced in response to diverse stimuli of ALI, including bacterial infection, lipopolysaccharide (LPS) exposure, sepis, trauma, hyperoxia, pharmaceutical exposure, and mechanical ventilation [241]. One of the major inducers of autophagy in ALI is increased oxidative stress, which has been shown to promote autophagy in a number of lung cell lines and animal models of lung injury [242–244]. However, the role of autophagy in ALI still remains controversial (Fig. 4) with studies suggesting both protective and deleterious effects of autophagy on ALI development [245–247]. A protective role for autophagy in ALI comes from studies showing that the loss of key autophagy genes, such as ATG7, ATG5, and ATG4b or autophagy inhibition with chloroquine, significantly increases the development of ALI in mice suggesting autophagy may have protective effects against the progression of ALI [241,244,248,249]. Thus, inhibiting mTOR activity, with rapamycin increases autophagy and reduces both LPS-induced pro-inflammatory cytokine production and lung injury [250,251]. Moreover, mTOR knockdown significantly attenuates LPS-induced airway inflammation and injury, indicating that autophagy functions as a protective mechanism in ALI [252].

Additionally, autophagy plays significant role in preventing sepsis. In aecal ligation and puncture (CLP) model of polymicrobial sepsis-induced ALI autophagy proteins are up-regulated in multiple organs, including heart, lungs, liver, and kidneys [253–256]. Zhao et al [256] has demonstrated that there were significant increases in the autophagy markers LC3-II and Beclin 1, and lysosome-related protein Rab7 and LAMP2 in ALI induced by sepsis. Genetic deletion of autophagy genes such as LC3B, BECN1 increases inflammation, organ injury, and mortality in septic mice induced by CLP [251,257]. Conversely, rapamycin or LC3 overexpression reduces inflammatory response and apoptotic cell death and improves the survival in mice subjected to CLP [254,255]. In the endotoxic shock model, macrophages lacking LC3 or Beclin 1 demonstrated increased caspase-1 activation, the accumulation of depolarized mitochondria, increased mROS, and the secretion of IL-1β and IL-1β [251]. Another pathway through which autophagy may be protective in ALI is associated with activation of Nrf2-regulated antioxidant responses to control oxidative stress and pulmonary injury [259–261]. Activation of Nrf2 with tert-butylhydroquinone (tBHQ) reduced LPS-induced lung injury in mice by promoting macrophages M2 polarization, increased tissue repair and reduced ROS production [261]. The lung injury associated with prolonged hyperoxia (elevated pO2)
exposure also increases in the overall expression of LC3 marker in both the mouse lung through elevations in ROS [262] and in human bronchial epithelial cells [263] further emphasizing the complex interplay between autophagy/mitophagy and ROS in ALI. Pharmacological Nr2 activation has been previously explored as a strategy to prevent and treat hyperoxia-induced ALI [264].

In contrast, several studies have shown that autophagy may have a detrimental role in ALI pathogenesis in certain circumstances [245,247, 265,266]. For instance, inhibition of autophagy ameliorates acute lung injury caused by mechanical ventilation [245,247]. Mechanical ventilation, while a life-saving intervention, can expose the lung to excessive mechanical stress that exacerbates the existing injury in established ARDS, a process known as ventilator-induced lung injury (VILI). Autophagy and oxidative stress contribute to the development of VILI. A growing body of evidence indicates that mechanical ventilation causes massive generation of mitochondrial ROS following mechanical stretch [267–269] and further promotes ROS generation from inflammatory cells [270]. LC3 expression increased in lung macrophages and genetic inhibition of autophagy abolished mechanical ventilation-induced NLRP3 inflammasome activation and subsequent release of IL-1β and IL-18 [247]. Similarly, ATG4b knockout mice also exhibited decreased NF-κB activation and alleviated inflammatory injury in response to VILI [245]. It has recently been reported that H2S (hydrogen sulfide) treatment could attenuate VILI through ROS formation inhibiting autophagy via the ROS/AMPK/mTOR pathway [271–273]. Subsequent studies have been performed to evaluate the effects of Nr2 activation in the protection against VILI. Sodium sulfate protects against VILI by upregulating Nr2 target genes involved in the restoration of redox balance [274]. Therefore, pharmacologically induced autophagy, and the subsequent activation of Nr2, may constitute a good approach for lung protection during mechanical ventilation.

In summary, autophagy and mitophagy can play protective or detrimental roles in ALI depending on the underlying cause of the lung injury, on the cell types, on the stage of lung injury (early phase or recovery phase), and at which step autophagy is inhibited.

4.3. Cystic fibrosis (CF)

Cystic fibrosis (CF) is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, leading to misfolding of the CFTR protein and damage to the lung among other organs [275–277]. The misfolding of CFTR leads to increased ROS, reduced autophagy, accumulation of misfolded proteins in the airway epithelia of CF patients and inflammation [160,278] (Fig. 4). Blocking the expression of mutant CFTR with Spautin-1 and homocysteine restores autophagic activity in CF [279,280]. Compounds such as VX-809 and VX-661 aim to restore proper CFTR folding reestablishing normal patterns of autophagy [277,281]. These findings demonstrate the importance of mutations in CFTR in the disruption of the autophagic process. Increased ROS in the airway epithelia could be the result of reduced levels of the antioxidant GSH in CFTR mutants, as demonstrated by lower GSH levels in CFTR-knockout mice and abnormal GSH efflux in CF [282–284]. Additionally, some patients with CF have increased levels of γ-glutamyltransferase (GGT), which catabolizes GSH to glutamate, that can exert ROS generation and inflammation in the airways [285,286]. Indeed, treatment with a ROS scavenger, such as N-acetylcysteine (NAC), or the synthetic superoxide dismutase (SOD) EUK 134 restores autophagic function [160]. ROS have also been shown to disrupt autophagy in CF by regulating the SUMOylation of TG2 leading to its activation and the crosslinking and sequestration of Beclin 1 with the PI3K complex III to form aggresomes. inhibition of TG2 with the proteostasis regulator cysteamine can restore the autophagic function and reduce inflammation in the airway epithelium [160,287]. Autophagy is also restored by directly promoting the expression of autophagy related protein, Beclin 1 [160]. Demethylation of the ATG12 promoter region with the natural product epigallocatechin-3-gallate (EGCG) increases ATG12 expression, and improves both autophagy and the immune response in CF [288]. Autophagy is also restored when the mTOR pathway is inhibited, suggesting that regulation of the mTOR pathway represents another avenue to restore autophagy in CF [289]. Together, these studies suggest that autophagy is a survival mechanism in the pathogenesis of CF, and pharmacological induction of autophagy might be a promising strategy to delay CF progression.

4.4. Idiopathic pulmonary fibrosis (IPF)

A growing body of evidence supports an important role of autophagy in idiopathic pulmonary fibrosis (IPF) [290–292] (Fig. 4). IPF is a chronic progressive lung disease characterized by scar tissue formation, lung function impairment and respiratory failure. Although IPF etiology is unclear, a number of major risk factors have been described including genetics, CS, air pollution, and aging [293]. The prevailing literature suggests that aging mitochondria and impaired autophagy/mitophagy are involved in IPF pathogenesis [294–297]. Excessive ROS generation produced by activation of several NOX isoforms induces aberrant redox signaling and disease progression in IPF (reviewed in Ref. [298]). Cross-talk between activated NOX isoforms and mitochondria also affects mitochondrial function and mtROS generation [299]. TGF-β-mediated activation of NOX4 is a major contributor to IPF development. NOX4 is widely distributed in different types of vascular cells and is the only NOX isoform which is up-regulated by TGFβ. Recent studies demonstrated a functional link between TGFβ-induced NOX4 levels and autophagy rate in bleomycin-exposed mice and fibroblasts derived from IPF patients [300]. NOX4 inhibition by metformin [301], NOX4 degradation by azithromycin [302] or miRNA-directed downregulation of TGFβR2/NOX4 [302] reverse or prevent bleomycin-induced pulmonary fibrosis in animals. The oxidative stress induced by NOX4 induces cell senescence resulting in a pro-apoptotic phenotype in alveolar epithelial cells (AEC) and an anti-apoptotic phenotype in senescent myofibroblasts leading to increased extracellular matrix (ECM) deposition and fibrotic foci formation. AEC senescence is accompanied by the loss of PTEN, and the activation of the NF-κB pathway [303]. Interestingly, fibroblasts cultured in the supernatants collected from senescent AEC also exhibit increased collagen deposition [303]. Mitochondria-targeted antioxidants reverse fibroblast senescence suggesting mtROS contribute to this process [304]. The analysis of lung tissue samples obtained from IPF patients shows an accumulation of p62 and low levels of LC3-II, and TGF-β1 treatment of lung fibroblasts also downregulates autophagy [305]. These data indicate that the molecular mechanisms underlying IPF development include impaired autophagy. Furthermore, stimulating autophagy with rapamycin decreases the expression of fibronectin and α-smooth muscle actin in fibroblasts in vitro and exerts an anti-fibrotic effect in the bleomycin model in vivo [305]. Detailed studies of autophagy in IPF have revealed that the accumulation of dysfunctional mitochondria is associated with Parkin [306] and PINK1 deficiency which, in turn, depends on a decrease in ATF3 transcription factor activity [294,307]. PINK1-deficient mice are prone to lung fibrosis and this is characterized by the accumulation of dysfunctional mitochondria [294]. The anti-fibrotic agent, pirfenidone, has been shown to improve autophagy/mitophagy by enhancing PARK2 expression and by decreasing mtROS levels and attenuating fibrosis in bleomycin-exposed mice [308]. The decrease in mitophagy in IPF also leads to extracellular release of mitochondrial damage associated molecular patterns (mtDAMPs), such as mtDNA, which induces pro-inflammatory cell signaling via TLR9 [309]. These can be been used as a plasma marker of severe IPF in patients [310, 311]. Molecular mechanisms associated with aging (such as genetic instability, epigenetic changes, aging-related histone PTMs etc.) may also contribute to mitochondria dysfunction and IPF pathogenesis [311]. Mucin 5B overexpression has been shown to enhance lung fibrosis in mice [312], suggesting a cross-talk between autophagy and secretory mechanisms. Further, increased expression of mucin 5B in the lungs of IPF patients has been recently linked to MUC5B

W. Ornatowski et al. Redox Biology 36 (2020) 101679
promoter polymorphisms and to alterations in its epigenetic regulation by DNA methylation [313]. Interestingly, in contrast to other hyperproliferative/fibrotic pulmonary diseases (such as PAH and asthma), autophagy impairment is a hallmark of IPF [294–297] and also characteristic for CF (see Section 4.3). Indeed, the systematic analysis of data obtained for various pulmonary diseases suggests that both an impaired and hyper-activated autophagy can have a negative impact on cell homeostasis and contribute to the development of disease pathology.

### 4.5. Pulmonary arterial hypertension (PAH)

Pulmonary artery hypertension (PAH) is a chronic disease characterized by abnormal proliferation of vascular wall cells (including pulmonary artery endothelial/PAEC, smooth muscle cells/PASMC, and fibroblasts), vascular remodeling and resistance, a decreased vessel lumen and high blood pressure followed by a fatal right heart failure. An excessive generation of ROS and reactive nitrogen species (RNS) along with mitochondrial dysfunction are characteristics for PAH and have been well-documented [269,314,315]. Moreover, in vitro and in vivo experiments with the drugs aimed at scavenging ROS/RNS or improving mitochondrial function have identified their central role in PAH development [316–318]. However, oxidative stress can induce autophagy [319] and increased autophagy may be important for PAH development (Fig. 4). Since autophagy is responsible for degradation of defective organelles including mitochondria, it has become clear that this may be involved in modulation of PAH progression and have a therapeutic potential. Indeed, recent studies of animal models of PAH, have investigated autophagy markers such as LC3, Beclin 1, p62 etc., and have concluded that autophagy is accelerated in the cells or lung tissue isolated from experimental models of PAH including mice exposed to chronic hypoxia, or rats treated with monocrotaline- or sugen/hypoxia-treated rats [144,320,321]. Autophagy also appears to be enhanced in lung tissue samples obtained from PAH patients [144]. A number of publications have demonstrated that increased autophagy promotes the development of PAH and is involved in the development of the hyperproliferative/anti-apoptotic phenotype in PAEC and PASMC. As a note, this phenotype is a cellular signature of PAH pathogenesis [322,323]. In concordance with these findings, several autophagy inhibitors have been tested in animal models and were able to attenuate PAH development. Lysosomal inhibitors, chloroquine and hydroxychloroquine, which inhibit autophagy by preventing autophagosome maturation, were reported to diminish proliferation of SMC and reduce PAH pathogenesis in monocrotaline-treated rats [320] and hypoxia-exposed mice [324]. Zhang and colleagues reported hypoxia-induced proliferation of PASMC can be reversed by another inhibitor of autophagy, 3-MA [323]. Hypoxia-induced activation of AMP-activated protein kinase (AMPKα-1) induces autophagy and is critical for human PASMC survival [325]. And vice-versa, inhibition of AMPK or activation of mTOR pathway can inhibit autophagy and have a negative effect on PAH progression [323,325]. Interestingly, the dietary flavonoid quercetin, induces apoptosis and potentiates hypoxia-induced autophagy in PASMCs through a FoxO1-SENS3-mTOR pathway [322,326]. Furthermore, PASMCs treated with autophagic inhibitors are more susceptible to quercetin-induced apoptosis, suggesting that combining quercetin and autophagy inhibitors could be a novel therapeutic strategy for treating hypoxia-associated PH.

### 4.6. Asthma

Asthma is a complex respiratory illness characterized by chronic airway inflammation and hyperreactivity, bronchoconstriction, mucus overproduction, and airway remodeling [327]. A number of studies have demonstrated the central role of oxidative stress in the pathogenesis of asthma [328,329], with increased levels of ROS in sputum and breath condensates positively correlating with disease severity [330,331]. Autophagy plays an important role in asthma being involved in several key features of asthma pathogenesis, including eosinophilic airway inflammation [332], airway hyperresponsiveness [333], and airway remodeling [334](Fig. 4). Increased autophagy levels have been detected in sputum granulocytes, neutrophils, peripheral blood eosinophils and peripheral blood cells of patients with asthma [333,335,336]. There are also more double-membrane autophagosomes in fibroblasts and epithelial cells in bronchial biopsy tissue from asthmatic patients than from a healthy subjects [335]. Genetic mutations in autophagy genes are also associated with asthma with single nucleotide polymorphisms (SNPs) in the autophagy gene, Atg5 correlating with reduced lung function [337] and promotion of airway remodeling in patients with severe asthma [335,337]. Further, SNPs in Atg5 and Atg7 are associated with the development of childhood asthma [333,338]. The activation of autophagy also correlates with the production of neutrophil extracellular traps (NETs) in neutrophils [339] and genetic polymorphisms of ATG5 and ATG7 contribute to neutrophilic airway inflammation in the pathogenesis of adult asthma [340]. Activation of autophagy in epithelial cell culture model systems exposed to allergens or other antigens, is also detrimental and promotes disease progression [341,342]. Genetic depletion of ATG5 and ATG14 or pharmacological inhibition of autophagy with 3-MA or bafilomycin A1 (Baf-A1) in epithelial cells treated with IL13 results in less mucus secretion and less CCL26 (eosinophil chemokine) production, demonstrating that autophagy is involved in the activation of the Th2 response in asthma [343].

There is a strong correlation between autophagy activation and asthma airway remodeling with higher expression of Beclin 1 and ATG5 along with reduced p62 in asthmatics compared with non-asthmatics [334]. Autophagy is also a regulator of TGF-β1-induced fibrogenesis [344] and autophagy inhibition using ATG5 deletion or treatment with Baf-A1 or 3-MA decreases the fibrotic effect of TGF-β1 [344]. Furthermore, mitochondrial dysfunction and elevated ROS production are also associated with asthma [345–347]. For example, fine particulate matter (PM2.5) increases ROS production, mitochondrial lipid peroxidation, disrupts mitochondrial dynamics and causes mitochondrial damage, which triggers the mitophagy via the PINK/Parkin pathway [348]. Thus, mitophagy may be critical in environmental pollutant-induced injury by removing damaged mitochondria and reducing excessive ROS. Moreover, genetic polymorphisms in the ATG5 gene are associated with autophagy and asthma. This finding, coupled with the fact that autophagy and mitophagy are enhanced in the asthmatic airway, suggests that autophagic pathway modulation has the potential to be a new therapeutic target in asthma treatment.

### 5. Therapeutic implications of autophagy dysregulation

Autophagy can both promote and perturb the pathogenesis of pulmonary diseases (Fig. 4). In some lung diseases, such as sepsis, autophagy appears to provide protection against bacterial infection and allow an inflammatory response. In the case of exposure to cigarette smoke, autophagy aggravates and promotes disease progression for many human lung diseases. To date the array of autophagy modulating therapeutics is mostly limited to experimental compounds. Currently, only a few compounds that can modulate autophagy have been evaluated for clinical use, including both activators of autophagy e.g., the mTOR inhibitor, rapamycin and inhibitors of autophagy e.g., chloroquine/hydroxychloroquine. Chloroquine/hydroxychloroquine has been explored as a cancer therapeutic [349,350]. However, the effectiveness of these compounds is a is limited by their off-target effects unrelated to the autophagy pathway. Thus, the pleiotropic effects of these compounds make it difficult to assign therapeutic effects directly to autophagy inhibition rather than other endpoints. However, the targeting of autophagy pathways might prove more beneficial than direct scavenging of ROS, which while capable of inhibiting damage, might also diminish the normal signals that act to augment autophagy. Thus, autophagy or mitophagy activators have the potential to prove to be significantly more efficacious that antioxidant therapies. Additional
candidate therapeutic compounds that modulate autophagy have been described, including a Tat-Beclin 1 peptide [351], inhibitors of histone deacetylases [352], activators of the AMPK pathway [353], and Vitamin D [354]. Given the important roles of autophagy in various lung diseases (Fig. 4), utilizing autophagy modulators could also improve the therapeutic effects of the current interventions in various lung diseases when used in combination.

Autophagy has also been shown to be induced by, and to protect against, the oxidative stress induced by numerous drugs used in cancer treatment. Various anti-cancer treatments have been shown to activate ROS-induced autophagy which in turn leads to either the development of cell drug resistance or to the induction of autophagy and/or apoptosis. Considering the complexity of cellular effects observed during cancer therapy, several treatments have been proposed, predicated on the importance of ROS as well as autophagy or apoptosis in the disease pathogenesis. Autophagy can be induced by, and to protect against, the oxidative stress induced by numerous drugs used in cancer treatment. Various anti-cancer treatments activate ROS-induced autophagy which in turn leads to either the development of drug resistance or to the induction of autophagy and/or apoptosis. Considering the complexity of cellular effects observed during cancer therapy, several treatments have been proposed, to take advantage of the importance of ROS, autophagy, and apoptosis in the disease pathogenesis. Thus, cancer therapy strategies are now trying to exploit ROS and autophagy to achieve cytotoxicity [355]. Some chemotherapy drugs are known to induce oxidative stress leading to autophagic cell death, such as arsenic trioxide (As$_2$O$_3$) and 2-methoxyestradiol (2-ME). As$_2$O$_3$ can induce apoptotic and autophagic cell death in many types of cancer cells [356] while ROS formation is essential for As$_2$O$_3$ cytotoxicity [357]. Similarly, 2-ME increases ROS levels by inhibiting complex I and mitochondrial SOD [358].

ROS generation induces both apoptosis and autophagy; thus combining ROS and autophagy inducing agents could produce synergistic tumor killing effects [355,359]. Therefore, it is likely that in the future, treatment strategies will be based on cell characteristics such as basal autophagy levels, beclin-1 expression, ROS levels, and apoptosis resistance. Targeting mitophagy alone also has therapeutic potential. For example, rapamycin and metformin, as general autophagy-inducing drugs, have been shown to attenuate AMPK and mTOR activity, preserving energy metabolism by regulating mitophagy and mitochondrial biogenesis [360]. In addition, several naturally occurring compounds, such as spermidine, resveratrol, urolitish A and certain antibiotics, have been shown to maintain mitochondrial integrity through the induction of mitophagy and the promotion of mitochondrial biogenesis [361]. Thus, although we are still some way from utilizing autophagy modulator therapies clinically, it is clear that oxidative stress and autophagy are key elements in the pathological progression of many pulmonary (and other) diseases, and that they interact in intricate and important ways (Fig. 3). A comprehensive clinical approach that considers the complex interplay between these important processes will be essential for successful therapeutic interventions in humans.

6. Conclusions and future perspectives

One of the most important biological responses in the cell that is regulated by ROS and oxidative stress is autophagy [6]. Autophagy provides a protective or adaptive function during the pathogenesis of diseases that involve components of metabolic or mitochondrial dysfunction, protein aggregation, inflammation, and oxidative stress. Thus, the interplay between ROS and autophagy is critical for cellular homeostasis and survival. Autophagy is now recognized to exert key functions in the pathogenesis of various human diseases [224] and multiple studies have indicated that the interplay between ROS and autophagy is highly relevant in the development of many pulmonary diseases (Fig. 4).

Oxidative stress is a complex phenomenon with important physiological and pathophysiological implications in many lung disorders. Our lack of a through basic understanding of when oxidative stress is a major driver of disease, coupled with an absence of standardized biomarkers that can easily define clinical or functional outcomes, likely plays a significant role in the lack of success in a number of antioxidant therapy trials. In the future oxidative stress will need to be framed in the context of individual (phenotypical and genetic) risk factors and environmental exposures, to determine which individuals are most likely to benefit from a particular therapy. This personalized medicine approach will necessitate the development of clinically relevant biomarkers. For example, the rational selection of patients entering clinical trials with autophagy inhibitors would require a robust set of autophagy-related biomarkers that can be followed longitudinally and allow the rapid determination of likely clinical outcome. However, even if a robust biomarker is identified, a number of other issues will need to be overcome such as differences in staining techniques, scoring systems and cut-off points, sensitivity due to limited sample sizes, and the need for dependent validation processes. One of the best studied autophagy-related proteins, LC3B, has long served as an autophagy marker in multiple in vitro assays. The association of high LC3B expression with aggressive disease and poor outcomes has been repeatedly reported in various cancers [362-364]. However, an increase or decrease in the expression levels of autophagosomal markers such as LC3B is difficult to monitor over time, especially in specific tissues and thus may not directly correlate with autophagic activity. Identifying appropriate biomarkers that will allow changes in autophagy to be accurately measured is a major challenge for clinical studies using autophagy modulators. In this context, novel biomarkers indirectly related to autophagic activity, such as autophagy products rather than the autophagy machinery, should be explored. Due to the dynamic nature of autophagy and the complexity of its regulation, simultaneous assessment of several autophagy markers will likely be required to assess autophagy status. However, many autophagy proteins have been shown to function in other cellular processes, including cell survival and apoptosis, modulation of cellular trafficking, protein secretion, cell signaling, transcription, translation and membrane reorganization [365]. Each protein known to be involved in the autophagy machinery, when evaluated separately from other autophagy proteins, could have an independent biomarker potential in pulmonary diseases. Thus, caution will be required when interpreting the results from studies that report association of disease expression of autophagy related proteins with clinicopathological characteristics and patient outcomes.

The diverse roles of autophagy in lung disease pathogenesis might also be due to the different types of lung diseases, the diverse stressors for the etiology, the various cell types in the lung, and the different mechanisms underlying disease initiation and progression. In addition, the analytical methods, experimental approaches, reagents, and models with different cells and animals all contribute to variations between laboratories. Further, it still remains unclear how cells orchestrate nonselective autophagy and selective autophagy during disease initiation and progression, and whether nonselective autophagy cross-talks with selective autophagy [246]. The lack of autophagy inhibitors to specifically target nonselective autophagy and selective autophagy in a given lung cell type also remains a major challenge for therapeutic intervention. Furthermore, some of studies have only examined LC3 accumulation which might be a result of the activation or inhibition of autophagic flux-mediated degradation. Therefore, an increased understanding of the complex role of autophagy in the pathogenesis of disease will facilitate targeting this pathway for therapeutic gain in specific diseases. Thus, we will need to define the various pathways of selective autophagy and their relevance to disease pathogenesis in acute detail to allow the development of appropriate therapeutic agents designed for different diseases.

In conclusion, in this review, we have provided an overview of cellular autophagy, and then focused on the interrelation between ROS and autophagy. ROS-induced autophagy could be either a cellular protective mechanism that alleviates oxidative stress, or a destructive
process. Autophagic degradation of Keap1 activates Nrf2 and protects against oxidative stress, while mitophagy and pexophagy regulates oxidative stress by degradation of ROS-producing organelles. Furthermore, macroautophagy and CMA play a major role in the degradation of oxidized proteins and aggregates. Finally, we discussed the interplay of ROS and autophagy in lung diseases including COPD, ALI, CF, IPF, PAH, and asthma. ROS-autophagy interaction plays a critical and complex role in the pathogenesis of these lung diseases. However, further investigation is needed to determine the underlying mechanisms and signaling pathways of the specific molecular interactions between ROS and autophagy. The appropriate adjustment of autophagy will be crucial for the development of new therapeutic strategies for chronic pathologies involving oxidative stress. Therefore, a new avenue for lung disease treatment might include combinations of antioxidants or autophagy inhibitors/activators.

Declaration of competing interest

The authors have no conflict of interest to declare related to this review article.

Acknowledgements

This research was supported in part by HL60190 (SMB), HL137282 (SMB/IRF), HL134610 (SMB), HL142212 (SMB/EZ), HL146369 (SMB), and HL061284 (JRF) all from the National Institutes of Health.

Abbreviations

| Acronym | Description |
|---------|-------------|
| 3-MA | 3-methyladenine |
| ALI | acute lung injury |
| AMPK | AMP-dependent protein kinase |
| Ang II | angiotensin II |
| AP-1 | activator protein 1 |
| ARDS | acute respiratory distress syndrome |
| ARE | antioxidant response element |
| Atg | autophagy related gene |
| Bcl2 | B-cell lymphoma 2 |
| Bnip3 | Bcl-2/adenovirus E1B 19-kDa-interacting protein 3 |
| CCCP | carbonyl cyanide m-chlorophenyl hydrazine |
| CF | cystic fibrosis |
| CFTR | cystic fibrosis transmembrane conductance regulator |
| CMA – C | chaperone mediated autophagy - carbon monoxide |
| CO | chronic obstructive pulmonary disease |
| CS | cigarette smoke |
| CSE | cigarette smoke extract |
| DRP1 | dynamin-related protein 1 |
| EpRE | electrophile response element |
| FIP200 | FAK-family interacting protein of 200 kDa |
| FoxO | forkhead BoxO |
| FUNDC1 | FUN14 domain-containing protein 1 |
| GSH | reduced glutathione |
| GTPase | guanosine triphosphatase |
| HIF-1α | hypoxia-induced factor-1α |
| HKII | hexokinase II |
| HLMVEC | human lung microvascular |
| H2O2 | hydrogen peroxide |
| HSPA9 | heat Shock Protein Family A (Hsp70) Member 9 |
| IPF | idiopathic pulmonary fibrosis |
| JAK2 | Janus kinase 2 |
| Keap1 | Kelch-like ECH-associated protein-1 |
| LC3B | microtubule-associated protein-1 light chain3B |
| LPS | lipopolysaccharide |
| Mfn | mitofusin |
| mtDNA | mitochondrial DNA |
| mROS | mitochondrial-derived reactive oxygen species |
| mTOR | mechanistic target of rapamycin |
| mTORC1 | mTOR complex 1 |
| NOX | NADPH oxidase |
| Nrf2 | nuclear factor erythroid 2-related factor 2 |
| O2•− | superoxide anion |
| PAH | pulmonary arterial hypertension |
| PASMC | pulmonary artery smooth muscles cells |
| P3K | phosphoinositide 3-kinase |
| P3P | binding autophagy-linked FYVE domain protein AMPK |
| PINK1 | PTEN-induced putative kinase 1 |
| p62/SQSTM1 | 62-kDa autophagic substrate protein, sequestosome-1 |
| PTEN | phosphatase and tensin homologue |
| RhoA | Ras homologous GTP-binding protein |
| ROS | reactive oxygen species |
| SMC | smooth muscle cells |
| SOD | superoxide dismutase |
| STAT1 | signal transducer and activator of transcription 1 |
| TG2 | translglutaminase |
| TGF-β | transforming growth factor β1 |
| TIGAR | P53-inducible glycolysis and apoptosis regulator |
| TNFα | tumor necrosis factor α |
| TSC2 | tuberous sclerosis 2 |
| TXNIP | thioredoxin-interacting protein |
| ULK1 | upstream kinase UNC51-like kinase 1 |
| UVRAG | ultraviolet radiation resistance-associated gene |
| VDAC1 | voltage-dependent anion-selective channel 1 |
| VILI | ventilator-induced lung injury |
| VPS34 | vacuolar protein sorting 34 |
| Δψm | mitochondrial membrane potential |

References

[1] D.J. Klionsky, S.D. Emr, Autophagy as a regulated pathway of cellular degradation, Science 290 (5497) (2000) 1717–1721.
[2] N. Mizushima, M. Komatsu, Autophagy: renovation of cells and tissues, Cell 147 (4) (2011) 728–741.
[3] G. Kroemer, G. Marino, B. Levine, Autophagy and the integrated stress response, Mol. Cell. 40 (2) (2010) 286–293.
[4] J. Doherty, E.H. Baehrecke, Life, death and autophagy, Nat. Cell Biol. 20 (10) (2018) 1110–1117.
[5] L. Galluzzi, E.H. Baehrecke, A. Ballabio, P. Boya, J.M. Bravo-San Pedro, F. Cecconi, A.M. Choi, C.T. Chu, P. Codogno, M.I. Colombo, A.M. Cuervo, J. Debnath, V. Deretic, J. Díkic, E.L. Edelstein, G.M. Fimia, S. Fuda, D.A. Gewirtz, D.R. Green, M. Hansen, J.W. Harper, M. Jaattela, T. Johansen, G. Juhánz, A. C. Kimmelman, C. Kraft, N.T. Kistakis, S. Kumar, B. Levine, C. Lopez-Otin, F. Madeso, S. Martens, J. Martinez-Arenas, A. Melencon, N. Mizushima, C. Munz, L.O. Murphy, J.M. Penninger, M. Piacentini, F. Reggiori, D.C. Rubinsztein, K. Ryan, L. Santambrogio, L. Scorrano, A.K. Simon, H.U. Simon, A. Simonens, N. Tavernarakis, S.A. Tooze, Y. Yoshimori, J. Yuan, Z. Yue, Q. Zhong, G. Kroemer, Molecular definitions of autophagy and related processes, EMBO J. 36 (13) (2017) 1811–1836.
[6] N. Mizushima, A brief history of autophagy from cell biology to physiology and disease, Nat. Cell Biol. 20 (5) (2018) 521–527.
[7] Z. Yang, D.J. Klionsky, Mammalian autophagy: core molecular machinery and signaling regulation, Curr. Opin. Cell Biol. 22 (2) (2010) 124–131.
[8] B. Ravikumar, S. Sarkar, J.E. Davies, M. Futter, G. A. Arcenio-Arecia, Z.W. Green-Whitman, M. Jimenez-Sanchez, V.I. Korolchuk, M. Lichtenberg, S. Luo, D.C. Massey, F.M. Menzies, K. Moreau, U. Nazaryan, M. Ronen, F.H. Siddiqi, B.R. Underwood, A.R. Winlow, D.C. Rubinsztein, Regulation of mammalian autophagy in physiology and pathophysiology, Physiol. Rev. 90 (4) (2010) 1383–1435.
[9] G. Juház, T.P. Neufeld, Autophagy: a forty-year search for a missing membrane source, PLoS Biol. 4 (2) (2006) e66.
[10] L. Galluzzi, F. Pietrocola, B. Levine, G. Kroemer, Metabolic control of autophagy, Cell 159 (6) (2014) 1263–1276.
[11] T. T. Tomita, D. J. Klionsky, Autophagy: molecular machinery for self-eating, Cell Death Differ. 12 (Suppl 2) (2005) 1542–1552.
[12] W.W. Li, J. Li, J.K. Bao, Microautophagy in mammalian cells revisiting a 40-year-old conundrum, Autophagy 7 (7) (2011) 673–682.
[13] I. Potolicchio, E. Nieves, A.M. Cuervo, L. Santambrogio, Autophagy in mammalian cells revisiting a 40-year-old conundrum, Autophagy 7 (7) (2011) 673–682.
W. Ornatowski et al. Redox Biology 36 (2020) 101679

13

[15] M. Sakai, N. Araki, K. Ogawa, Lysosomal movements during heterophagy and autophagy: with special reference to neutrophilic lysosome and wrapping lysosome, J. Electron. Microsc. Tech. 12 (1989) 101–136.

[16] J.F. Dice, Peptide sequences that target cytosolic proteins for lysosomal proteolysis, Trends Biochem. Sci. 15 (8) (1990) 305–309.

[17] S. Kaurshik, A.M. Cuervo, The coming of age of chaperone-mediated autophagy, Nat. Rev. Mol. Cell Biol. 10 (2009) 365–381.

[18] S.J. Orenstein, A.M. Cuervo, Chaperone-mediated autophagy: molecular mechanisms and physiological relevance, Semin. Cell Dev. Biol. 21 (7) (2010) 719–726.

[19] J.C. Fare, S. Subramani, Mechanistic insights into selective autophagy pathways: lessons from yeast, Nat. Rev. Mol. Cell Biol. 17 (9) (2016) 537–552.

[20] D. Gatica, V. Lahiri, D.J. Kliene, Cargo recognition and degradation by selective autophagy, Nat. Cell Biol. 20 (3) (2018) 397–406.

[21] Y. Hirota, Y. Aoki, T. Kanki, [Mitophagy: selective degradation of mitochondria by autophagy], Sekigaku 83 (2011) 126–130.

[22] I. Kim, S. Rodriguez-Enriquez, J.J. Lemasters, Selective degradation of mitochondria by mitophagy, Arch. Biochem. Biophys. 462 (2) (2007) 245–253.

[23] D.H. Cho, Y.S. Kim, D.S. Jo, S.K. Cho, E.K. Jo, Pexophagy: molecular mechanisms and implications for health and diseases, Mol. Cell 41 (1) (2011) 55–64.

[24] E. Gobero, F. Reggiori, C. Kraft, Reticulophagy and ribophagy: regulated degradation of protein production factories, Int. J. Cell Biol. 2012 (2012) 188284.

[25] Y.E. Park, Y.K. Hayashi, G. Bonne, M. Komatsu, I. Nishida, Autophagic degradation of nuclear components in mammalian cells, Autophagy 5 (6) (2009) 795–804.

[26] F.C. Baltanas, I. Casafont, E. Weruaga, J.R. Alonso, M.T. Berciano, M. Lafarga, Y.E. Park, Y.K. Hayashi, G. Bonne, T. Arimura, S. Noguchi, I. Nonaka, I. Nishino, E. Cebollero, F. Reggiori, C. Kraft, Reticulophagy and ribophagy: regulated degradation of protein production factories, Int J Cell Biol 2012 (2012) 182834.

[27] J.H. Hurley, L.N. Young, Mechanisms of autophagy initiation, Annu. Rev. Genet. 43 (2009) 67–93.

[28] A. Overbye, M. Fengsrud, P.O. Seglen, Proteomic analysis of membrane-associated proteins from rat liver autophagosomes, Autophagy 3 (4) (2007) 300–322.

[29] H.C.L. Chan, S.M. Cronan, A.R. Bhattacharyya, J.A. Haspel, A. Singh, J. F. Sathirapongsasuti, M. Cervo, H. Yao, A.L. Chung, K. Mizumura, C.H. An, M. Hayashi-Nishino, N. Fujita, T. Noda, A. Yamaguchi, T. Yoshimori, A. Yoshimura, Y. Tamai, K. Wada, T. Kabuta, Discovery of a novel type of autophagy targeting RNA, Autophagy 9 (3) (2013) 403–409.

[30] B. Levine, Eating oneself and unlimited guests: autophagy-related pathways in cellular defense, Cell 120 (2) (2005) 159–162.

[31] A. Overbye, M. Fengsrud, P.O. Seglen, Proteomic analysis of membrane-associated proteins from rat liver autophagosomes, Autophagy 3 (4) (2007) 300–322.

[32] H.C.L. Chan, S.M. Cronan, A.R. Bhattacharyya, J.A. Haspel, A. Singh, J. F. Sathirapongsasuti, M. Cervo, H. Yao, A.L. Chung, K. Mizumura, C.H. An, M. Hayashi-Nishino, N. Fujita, T. Noda, A. Yamaguchi, T. Yoshimori, A. Yoshimura, Y. Tamai, K. Wada, T. Kabuta, Discovery of a novel type of autophagy targeting RNA, Autophagy 9 (3) (2013) 403–409.

[33] B. Levine, Eating oneself and unlimited guests: autophagy-related pathways in cellular defense, Cell 120 (2) (2005) 159–162.

[34] A. Overbye, M. Fengsrud, P.O. Seglen, Proteomic analysis of membrane-associated proteins from rat liver autophagosomes, Autophagy 3 (4) (2007) 300–322.

[35] H.C.L. Chan, S.M. Cronan, A.R. Bhattacharyya, J.A. Haspel, A. Singh, J. F. Sathirapongsasuti, M. Cervo, H. Yao, A.L. Chung, K. Mizumura, C.H. An, M. Hayashi-Nishino, N. Fujita, T. Noda, A. Yamaguchi, T. Yoshimori, A. Yoshimura, Y. Tamai, K. Wada, T. Kabuta, Discovery of a novel type of autophagy targeting RNA, Autophagy 9 (3) (2013) 403–409.

[36] B. Levine, Eating oneself and unlimited guests: autophagy-related pathways in cellular defense, Cell 120 (2) (2005) 159–162.

[37] A. Overbye, M. Fengsrud, P.O. Seglen, Proteomic analysis of membrane-associated proteins from rat liver autophagosomes, Autophagy 3 (4) (2007) 300–322.
S. Sciarretta, M. Volpe, J. Sadoshima, NOX4 regulates autophagy during energy deprivation, Autophagy 10 (4) (2014) 699–207.

R. Scherz-Shouval, E. Shvets, Y. He, Role and regulation of autophagy and apoptosis by nitric oxide in hepatic steatotic cells during acute liver failure, Liver Int. 37 (5) (2017) 1651–1659.

X. Zhang, L. Jin, Z. Tian, J. Wang, Y. Jiang, Y. Liu, Y. Chen, T. Chen, Y. Zhao, Y. He, Regulation of autophagy and apoptosis by nitric oxide in hepatic steatotic cells during acute liver failure, Liver Int. 37 (5) (2017) 1651–1659.

J. Sadoshima, Activation of NADPH oxidase 4 in the endoplasmic reticulum mitochondria-dependent apoptosis in cathepsin S-targeted tumor cells, PLoS One 13 (12) (2018), e0209444.

S. Datta, S. Chakraborty, C. Panja, S. Ghosh, Reactive nitrogen species control autophagy and apoptosis in K562 cells: implication of Tap1/2a induction in controlling autophagy, Free Radic. Res. 52 (4) (2018) 491–506.

L. Jin, H. Gao, J. Wang, S. Yang, J. Wang, J. Liu, Y. Yang, Y. Tan, T. Chen, Y. Zhao, Y. He, Reactive nitrogen species and apoptosis by nitric oxide in hepatic steatotic cells during acute liver failure, Liver Int. 37 (5) (2017) 1651–1659.

S. Sciarretta, M. Azad, S.A.B. Gibson, Superoxide is the major reactive oxygen species regulating autophagy, Cell Death Differ. 16 (7) (2009) 1040–1052.

R.J. Youle, D.P. Narendra, Mechanisms of mitophagy, Nat. Rev. Mol. Cell Biol. 12 (1) (2011) 9–14.

M. Komatsu, H. Kurokawa, S. Waguri, K. Taguchi, A. Kobayashi, Y. Ichiyama, S. Susi, I. Ueno, A. Sakamoto, K.I. Tong, M. Kim, Y. Nishito, S. Iemura, T. Natsume, T. Ueno, E. Komimani, H. Motoshob, K. Tanaka, M. Yamamoto, The selective autophagy substrate p62 activates the stress responsive transcription factor Nrf2 through inactivation of Keap1, Nat. Cell Biol. 12 (3) (2010) 213–222.

M. Dodson, M. Redmann, N.S. Rajasekaran, V. Darley-Usmar, J. Zhang, KEAP1-NRF2 signalling and autophagy in protection against oxidative and reductive proteotoxicity, Biochem. J. 469 (3) (2015) 347–355.

S. Kageyama, T. Saito, M. Ohta, R.H. Koide, Y. Ichiyama, M. Komatsu, Negative regulation of the Keap1- Nrf2 pathway by a p62/Scramabin splice variant, Mol. Cell Biol. 38 (7) (2018).

S.D. Chen, J.L. Yang, T.K. Lin, D.I. Yang, Emerging roles of sestrins in neurodegenerative diseases: countering oxidative stress and beyond, J. Clin. Med. 8 (7) (2019) 266.

Q. Gao, Oxidative stress and autophagy, Adv. Exp. Med. Biol. 1206 (2019) 179–198.

A. Panday, M.K. Sahoo, D. Osorio, S. Batra, NADPH oxidases: an overview from structure to innate immunity-associated pathways, Cell. Mol. Immunol. 12 (1) (2015) 5–23.

Y. Cui, Y. Wang, G. Li, W. Ma, X.S. Zhou, J. Wang, B. Liu, The Nox1/Nox4 inhibitor attenuates acute lung injury induced by ischemia-reperfusion in mice, PLoS One 13 (12) (2018) e0209444.

Y. He, Z. Sang, Y. Zhuo, X. Wang, Z. Guo, L. He, C. Zeng, H. Dai, Transport stress induces pig jejunal tissue oxidative damage and results in apoptosis/mitophagy activation, J. Anim. Physiol. Anim. Nutr. 103 (3) (2019) 1521–1529.

R.I. Deng, J. Su, S. Velak, C. Guan, A. Eir, E. Shi, G.F. Conord, Cross talk between NADPH oxidase and autophagy in pulmonary artery endothelial cells with intracellular persistent pulmonary hypertension, Am. J. Physiol. Lung Cell Mol. Physiol. 302 (7) (2012) L651–L663.

S. Wang, L.Y. Li, J. Li, J.M. Li, Mitochondrial reactive oxygen species leading to AMPK activation, Cell. Signal. 53 (2019) 327–338.

K. Belabebi, E. Cezelier, A. Desteet, B. Grenier, M.C. Chartier-Harlin, NADPH oxidases in Parkinson’s disease: a systematic review, Mol. Neurodegener. 12 (1) (2017) 1–13.

Y. Zhang, S. Ren, Y. Gu, J. Wang, L. Sun, W. Xue, X. Wang, J. Shen, Naringin attenuates cerebral ischemia-reperfusion injury through inhibiting peroxinitrite-mediated mitophagy activation, J. Mol. Neurodegener. 12 (1) (2017) 1–13.

J. Lee, S. Giordano, J. Zhang, Autophagy, mitochondria and oxidative stress: cross-talk and redox signalling, Biochem. J. 441 (2) (2021) 523–540.

H. Zhang, X. Kong, J. Kang, S. Yu, L. Li, J. Zhang, L. Sun, Oxidative stress induces parallel autophagy and mitochondria dysfunction in human glioma U251 cells, Toxicol. Sci. 110 (2) (2009) 376–388.

S. Scherz-Shouval, U. Shvetz, E. Fux, H. Shorer, L. Gil, Z. Elazar, Reactive oxygen species are essential for autophagy and specifically regulate the activity of Atg4, EMBO J. 26 (7) (2007) 1749–1760.

D. Mondaca-Ruff, J.A. Riquelme, C. Quiroga, I. Norambeuma-Soto, F. Sanchez-Orozco, P. Villas-Vallejo, M. Fernandez-Diaz, N. Lin, J.M. Martin, L. Garcia, S. Lavandera, M. Chiong, Angiotensin II-regulated autophagy is required for vascular smooth muscle cell hypertrophy, Front. Pharmacol. 9 (2018) 1553.

L. Li, Q. Luo, L. Yuan, C. Mao, X. Wu, X. Xiao, L. Sun, E. Ma, JNK-dependent Atg4A regulation mediates asparagine derivative BB-induced autophagy in MCF-7 cells, Toxicol. Appl. Pharmacol. 263 (1) (2012) 21–31.

L. Zhang, H. Wang, J. Xu, J. Zhu, K. Ding, Inhibition of cathepsin S induces autophagy and apoptosis in human glioblastoma cell lines through ROS-mediated P13K/AKT/mTOR/p70S6K and JNK signaling pathways, Toxicol. Lett. 228 (3) (2014) 248–259.

J. Zhang, J. Kim, A. Kim, C. Cai, D.N. Tripathi, R. Dere, A.R. Tee, J. Tait-Muldner, A. Di Narbo, J.M. Han, E. Kwiakowski, E.A. Dunlop, K.M. Dodd, R. Dodds, F. Czabotar, P.L. Faust, G. Wallis, J. Lemos, A. Verkhusha, V. Huisman, J. Holm, D. Koenig, L. Martin, L. Garcia, S. Lavandera, M. Chiong, Angiotensin II-regulated autophagy is required for vascular smooth muscle cell hypertrophy, Front. Pharmacol. 9 (2018) 1553.
induces ROS-mediated autophagy by regulating sestrin, AMPK, and mTOR level in mice, Redox Rep. 28 (4) (2019) 27–33.

[134] R.K. Nayak, D. Nataraj, J. Bhat, C.M. Friedrichs, R.T. Day, D.D. New, J.W. P. Fitzgerald, A. Ed, T. Denapoli, D.J. Parekh, Y. Gorin, K. Block, Stabilization of HIF-2alpha through redox regulation of mTORC2 activation and initiation of mRNA translation, Oncogene 32 (26) (2013) 3174–3155.

[135] M. Bernard, B. Yang, X. Shen, J. Yang, M. Bueche, M.A. Olivier, G. B. Cardin, M. El-Diwany, K. Underwood, F. Rodier, M.J. Hebert, Autophagy drives fibroblast senescence through mTORC2 regulation, Autophagy (2020) 1–15.

[136] R. Botot, R. Garcia-Medina, P. Gounain, J. Cichon, D. Ron, J. Fouyssoung, N. M. Mazure, Hypoxia-induced autophagy is mediated through hypoxia-inducible factor binding of BNIP3 and BNIPFL via their BH3 domains, Mol. Cell. Biol. 29 (10) (2009) 2570–2581.

[137] L.C. Chandel, E. Miao, E. Goldwasser, C.E. Mathieu, M.C. Simon, P. T. Schumacker, Mitochondrial reactive oxygen species trigger hypoxia-induced transcription, Proc. Natl. Acad. Sci. U. A. 95 (20) (1998) 11715–11720.

[138] J.K. Brunelle, E.L. Bell, N.M. Quesada, K. Vercauteren, V. Tiranti, M. Zeviani, R.C. Scarpulla, N.S. Chandel, Oxygen sensing requires mitochondrial ROS but not oxidative phosphorylation, Cell Metabol. 1 (5) (2005) 409–414.

[139] N.S. Chandel, D.S. McClintock, C.E. Feliciano, T.M. Wood, J.A. Melendez, A. J. Heo, K.W. Raines, V. Mocanu, S.L. Campbell, Redox regulation of RhoA, J. Biol. Chem. 285 (33) (2000) 25130–25138.

[140] D. Mottet, V. Dumont, Y. Decchave, C. Demaily, N. Nizami, M. Raes, C. Michiels, Regulation of hypoxia-inducible factor-1 alpha protein level during hypoxic conditions by the phosphatidylinositol 3-kinase/Akt/glycogen synthase kinase 3beta pathway in HepG2 cells, J. Biol. Chem. 278 (33) (2003) 31277–31285.

[141] J. Zhang, C. Chang, X. Jiang, L. Li, D. Zhang, T. Tang, Y. Tan, Q. Zhang, H. Yuan, J. Yu, J. Hu, D. Huang, Involvement of autophagy in hypoxia-mediated signaling to promote epidermal keratinocyte migration, Cell Death Dis. 10 (3) (2019) 234.

[142] I. Papandreu, A.L. Lim, K. Laderoute, N.C. Denko, Hypoxia signals autophagy in tumor cells via Akt activation, independent of HIF-1, BNIP3, and BNIP3L, Cell Death Differ. 15 (10) (2008) 1572–1581.

[143] K.M. Rouschop, T. van den Beucken, L. Dubois, H. Niessen, J. Bussink, E. Ferro, L. Goitre, S.F. Retta, L. Trabalzini, The interplay between ROS and ras network is the principal suspect for autophagy commitment, Autophagy 6 (7) (2010) 461–467.

[144] G. Bellot, R. Garcia-Medina, P. Gounon, J. Chiche, D. Roux, J. Pouyssegur, N. W. Ornatowski et al., Regulation of hypoxia-inducible factor-1alpha protein level during hypoxic stress in mitochondria and clearance, Biochim. Biophys. Acta 1843 (9) (2014) 2012–2021.

[145] B. Xiao, J.Y. Goh, L. Xiao, H. Xian, K.L. Lim, Y.C. Liou, Reactive oxygen species trigger Parkin/PINK1 pathway-dependent mitophagy by inducing mitochondrial depolarization recruits Parkin to damaged mitochondria and activates latent Parkin for mitophagy, J. Cell Biol. 189 (2) (2010) 211–221.

[146] C. Vives-Bauza, C. Zhou, Y. Huang, M. Cui, R.L. de Vries, J. Kim, J. May, M. A. Tocilesu, W. Liu, H.S. Ko, J. Magrane, D.M. Hoare, M. V. Dawson, R. Grahlbe, T. M. Dawson, C. Li, K. Tieu, S. Przedborski, PINK1-dependent recruitment of Parkin to mitochondria in mouse brain, Proc. Natl. Acad. Sci. U. A. 107 (10) (2010) 478–838.

[147] J.W. Harper, A. Orlaneus, J.M. Heo, Building and decoding ubiquitin chains for mitophagy, Nat. Rev. Mol. Cell Biol. 19 (2) (2018) 93–108.

[148] N. Matsuda, S. Sato, K. Shiba, K. Okatsu, K. Saito, C.A. Gautier, Y.S. Sou, S. Saiki, S. Kawajiri, F. Sato, M. Nishimura, K. Ono, K. Tanaka, PINK1-mediated stabilization by mitochondrial depolarization recruits Parkin to damaged mitochondria and activates latent Parkin for mitophagy, J. Cell Biol. 189 (2) (2010) 211–221.

[149] Y. Kurihara, T. Kanki, Y. Aski, Y. Hirota, T. Saigusa, T. Uchiumi, D. Kang, Mitophagy plays an essential role in reducing mitophagy-producing conditions, Nat. Rev. Mol. Cell Biol. 12 (3) (2011) 21–31.
W. Ornatowski et al.  Redox Biology 36 (2020) 101679
Impaired mitophagy leads to cigarette smoke-induced cellular senescence: implications for chronic obstructive pulmonary disease, Faseb J. (2017) 2912–2925.

D. Zhang, J. Zhou, L.C. Ye, J. Li, W. Bao, G. Wu, Y. Wang, Exogenous H2S inhibits autophagy in unilateral unrestrictive obstruction mouse renal tubule cells by regulating the ROS-AMPK signaling pathway, Cell. Physiol. Biochem. 49 (6) (2018) 2200–2213.

R. Malaviya, J.D. Laskin, D.I. Laskin, Oxidative stress-induced autophagy: role in pulmonary toxicity, Toxicol. Appl. Pharmacol. 275 (2) (2014) 145–151.

D. Zhang, J. Zhou, L.C. Ye, J. Li, W. Bao, G. Wu, Y. Wang, Exogenous H2S inhibits autophagy in unilateral unrestrictive obstruction mouse renal tubule cells by regulating the ROS-AMPK signaling pathway, Cell. Physiol. Biochem. 49 (6) (2018) 2200–2213.

S. Lo, S.S. Yuan, C. Hsu, Y.J. Cheng, Y.F. Chang, H.W. Hsueh, P.H. Lee, Y.C. Hsieh, L.Y. Liu, C. Zhu, C. Zhang, J. Liu, Y.Y. Li, W. Takahashi, E. Watanabe, L. Fujimura, H. Watanabe-Takano, H. Yoshidome, P.A. Aguirre, L. Tran, C. Ji, I. Ni, T. Min, D. Tang, N. Vij, Role of cigarette smoke-induced autophagy in pulmonary epithelium promotes LPS-induced acute lung injury, Autophagy 12 (12) (2016) 2273–2281.

J. Wei, G. Chen, X. Shi, H. Zhou, M. Liu, Y. Chen, D. Feng, P. Zhang, L. Wu, X. Lu, Nrf2 activation protects against intratracheal LPS induced mouse/marine respiratory distress syndrome by regulating macrophage polarization, Biochem. Biophys. Res. Commun. 500 (3) (2018) 790–796.

A. Tanaka, Y. Jin, J.S. Lee, M. Zhang, H.P. Kim, D.B. Stoka, S.W. Ryter, A.M. Choi, Hyperoxia-induced LC3II interacts with the Fas apoptotic pathway in epithelial cell death, Am. J. Respir. Cell Mol. Biol. 46 (4) (2012) 507–514.

X. Wang, Y. Wang, H.P. Kim, K. Nakahira, S.W. Ryter, A.M. Choi, Carbon monoxide protects against hyperoxic-induced epithelial cell apoptosis by inhibiting reactive oxygen species formation, J. Biol. Chem. 282 (3) (2007) 1718–1726.

N.M. Reddy, V. Suryanarayana, M.S. Yates, S.R. Kleeberg, P.M. Hamsou, M. Yamamoto, K.T. Liby, M.A. Sporn, T.W. Kessler, S.P. Hadji, The trisperinoid CDDO-imidazolide confers potent protection against hyperoxic acute lung injury in mice, Am. J. Respir. Crit. Care Med. 180 (9) (2009) 867–874.

R. Hu, Z.F. Chen, J. Yan, Q.F. Li, Y. Huang, H. Xu, Z. Jiang, L. Gao, M. Choi, Suppression of CFTR expression via interaction between DNA methylation and histone H3K27me3 in mouse liver, Cell Death Dis. 9 (2) (2018) R160.
A.C. Racanelli, S.A. Kikkers, A.M.K. Choi, S.M. Cloonan, Autophagy and R.S. Nho, P. Hergert, IPF fibroblasts are desensitized to type I collagen matrix-
A. Wree, L.P. Bechmann, N. Kumarasamy, U. Sommerwerck, C. Jochum, H. Jakob, R. Reilly, M.S. Mroz, E. Dempsey, K. Wynne, S.J. Keely, E.F. McKone, C. Hiebel, K. Caution, A. Pan, K. Krause, A. Badr, K. Hamilton, A. Vaidya, H. Gosu, K. Daily, A. Ricci, E. Cherubini, D. Scozzi, V. Pietrangeli, L. Tabbi, S. Raffa, L. Leone, C. Veith, A.W. Boots, M. Idris, F.J. van Schooten, A. van der Vliet, Redox K. Kato, L. Hecker, NADPH oxidases: pathophysiology and therapeutic potential
A.V.H. Leonard, W. Velsor, Brian J. Day, Antioxidant imbalance in the lungs of M. Fierro-Fernandez, O. Busnadiego, P. Sandoval, C. Espinosa-Diez, E. Blanco-
N. Sato, N. Takasaka, M. Yoshida, Y. Fujita, N. Tsuchiya, H. Utsumi, H. Yangagiwa, M. Hashimoto, H. Waku, J. Kojima, K. Shimizu, T. Numata, M. Kawadai, Y. Kaneko, H. Anso, M. Yamashita, M. Onda, T. Morikawa, K. Nakayama, K. Kuwano, Involvement of PARK2-mediated mitophagy in idiopathic pulmonary fibrosis pathogenesis, J. Immunol. 197 (2) (2016) 504–516.
M. Bueno, J. Brands, M.A. Gavrilin, M.E. Drew, E. Cormet-Boyaka, X. Chen, D. Shao, C. Brandsdorfer, J. Winkler, C. Blaul, J. Faunce, H. Pan, T. Woolard, A. Tsouveleki, D.E. Antin-Ozerkis, J.T. Puchalski, M. Slade, A.L. Gonzalez, D. C. Brandsdorfer, J. Winkler, C. Blaul, J. Faunce, H. Pan, T. Woolard, A. Tsouveleki, D.E. Antin-Ozerkis, J.T. Puchalski, M. Slade, A.L. Gonzalez, D. C. Brandsdorfer, J. Winkler, C. Blaul, J. Faunce, H. Pan, T. Woolard, A. Tsouveleki, D.E. Antin-Ozerkis, J.T. Puchalski, M. Slade, A.L. Gonzalez, D. C. Brandsdorfer, J. Winkler, C. Blaul, J. Faunce, H. Pan, T. Woolard, A. Tsouveleki, D.E. Antin-Ozerkis, J.T. Puchalski, M. Slade, A.L. Gonzalez, D. C. Brandsdorfer, J. Winkler, C. Blaul, J. Faunce, H. Pan, T. Woolard, A. Tsouveleki, D.E. Antin-Ozerkis, J.T. Puchalski, M. Slade, A.L. Gonzalez, D. C. Brandsdorfer, J. Winkler, C. Blaul, J. Faunce, H. Pan, T. Woolard, A. Tsouveleki, D.E. Antin-Ozerkis, J.T. Puchalski, M. Slade, A.L. Gonzalez, D. C. Brandsdorfer, J. Winkler, C. Blaul, J. Faunce, H. Pan, T. Woolard, A. Tsouveleki, D.E. Antin-Ozerkis, J.T. Puchalski, M. Slade, A.L. Gonzalez, D. C. Brandsdorfer, J. Winkler, C. Blaul, J. Faunce, H. Pan, T. Woolard, A. Tsouveleki, D.E. Antin-Ozerkis, J.T. Puchalski, M. Slade, A.L. Gonzalez, D. C. Brandsdorfer, J. Winkler, C. Blaul, J. Faunce, H. Pan, T. Woolard, A. Tsouveleki, D.E. Antin-Ozerkis, J.T. Puchalski, M. Slade, A.L. Gonzalez, D. C. Brandsdorfer, J. Winkler, C. Blaul, J. Faunce, H. Pan, T. Woolard, A. Tsouveleki, D.E. Antin-Ozerkis, J.T. Puchalski, M. Slade, A.L. Gonzalez, D. C. Brandsdorfer, J. Winkler, C. Blaul, J. Faunce, H. Pan, T. Woolard, A. Tsouveleki, D.E. Antin-Ozerkis, J.T. Puchalski, M. Slade, A.L. Gonzalez, D.
